

## **EXHIBIT B**

**EXHIBIT B**

U.S. Patent No. 7,604,929 B2

The prosecution history for U.S. Patent No. 7,604,929 B2

Declaration of Daniel Dryden (executed June 21, 2010).

Ostrowska *et al.*, "*Investigation of functional and morphological integrity of freshly isolated and cryopreserved human hepatocytes*," 1 Cell and Tissue Banking 155-168 (2000).

Shibata *et al.*, "*Prediction of Hepatic Clearance and Availability by Cryopreserved Human Hepatocytes: An Application of Serum Incubation Method*," 30 Drug Metabolism and Disposition 892-896 (2002).

Oehninger *et al.*, "*Aessment of sperm cryodamage and strategies to improve outcome*," 169 Molecular and Cellular Endocrinology 3-10 (2000).

Hengstler *et al.*, "*Cryopreserved Primary Hepatocytes as a Constantly Available In Vitro Model for the Evaluation of Human and Animal Drug Metabolism and Enzyme Induction 1*," 32 Drug Metabolism Reviews 81-118, Abstract (2002).

Arikura *et al.*, "*UW solution: a promising tool for cryopreservation of primarily isolated rat hepatocytes*," 9 Journal of Hepatobiliary Pancreatic Surgery 742-749 (2002).

Marsh *et al.*, "*Hypothermic Preservation of Hepatocytes III Effects of Resuspension Media on Viability after up to 7 Days of Storage*", 13(3) Hepatology 500-508 (1991).

Srnzova *et al.*, "*Optimisation of Porcine Hepatocyte Cryopreservation by Comparison of Viability and Enzymatic Activity of Fresh and Cryopreserved Cells*," 70 Acta Veterianaria Brno 141-147 (2001).

Vincent *et al.*, "*Adjustment of the Osmolality of Percoll for the Isopycnic Separation of Cells and Cell Organelles*," 141 Analytical Biochemistry 322-328 (1984).

Adams *et al.*, "*Effective Cryopreservation And Long- Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation And Replicative Potential*," 4(6) Cell Transplantation 579-586 (1995).

Alexandre *et al.*, "*Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies*," 44 Cryobiology 103-113 (2002).

Anand "*Bioartificial Livers: The State Of The Art*," 17(4) Tropical Gastroenterology 197-198, 202-211 (1996).

Berry *et al.*, "*Techniques for Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions*," 51(1) Life Sciences 1-16 (1992).

Burlina "*Hepatocyte Transplantation For Inborn Errors Of Metabolism*," 27(3) *Journal of Inherited Metabolic Disease* 373-83 (2004).

Chan *et al.*, "*Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies*," 10(10) *Liver Transplantation* 1331-1342 (2004).

Chesne *et al.*, "*Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation*," 18(2) *Hepatology* 406-414 (1993).

Coundouris *et al.*, "*Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies*," 23(12) *Xenobiotica* 1399-1409 (1993).

Diener *et al.*, "*A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics*," 30(2) *Cryobiology* 116-127 (1993).

Dou *et al.*, "*Thawed Human Hepatocytes In Primary Culture*," 29(4) *Cryobiology* 454-69 (1992).

Fox *et al.*, "*Hepatocyte Transplantation*," 6 (4 Suppl.) *American Journal of Transplantation*. 7-13 (2004).

Fukuda *et al.*, "*Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver*," 27(12) *International Journal of Artificial Organs* 1091-1099 (2004).

Gan *et al.* "*Hybrid Artificial Liver Support System For Treatment of Severe Liver Failure*," 11(6) *World Journal of Gastroenterology* 890-894 (2005).

Gomez-Lechon *et al.*, "*Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism in Man*," 5(5) *Current Drug Metabolism* 443-462 (2004).

Guillouzo *et al.*, "*Isolated and Cultured Hepatocytes*," Paris: les Editions INSERM and London: John Libbey Eurotext (1986).

Hewitt *et al.*, "*Cyropreserved Rat, Dog and Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures*," 23(6) *Human & Experimental Toxicology* 307-316 (2004).

Horslen "*Hepatocyte Transplantation*," 77(10) *Transplantation* 1481-1486 (2004).

Houle *et al.*, "*Retention Of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes*," 31(4) *Drug Metabolism and Disposition* 447-451 (2003).

Kasai *et al.*, "*Large Scale Cryopreservation of Isolated Dog Hepatocytes*," 30 *Cryobiology* 1-11 (1993).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Multiple Donor Pooled Cryopreserved Human Hepatocytes*" (Exhibit E.1).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*CellzDirect Hepatic Products List*" (Exhibit E.2).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Product Characterization Sheet – Lot #: HuP58*" (Exhibit E.3).

Screen Shot from [www.apscienc.com](http://www.apscienc.com); "*Human Hepatocytes*" (Exhibit E.4).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); (2006) "*CellzDirect enters into 5 year exclusive partnership with Advanced Pharmaceutical Sciences, Inc.*" (Exhibit E.5).

Li *et al.* (2010) "*Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes*" in *Enzyme Inhibition in Drug Discovery*, eds. Lu *et al.*, John Wiley & Sons, Inc., Hoboken, New Jersey (Exhibit E.6).

Li "*In Vitro Adverse Drug Effects (ADE) Screening Assays*" Presentation (Exhibit E.7).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Produce Applications*" (Exhibit E.8).

Li (2009) Institute for Scientific Exchange DDI-2009 Conference "*Use of Pre-Pooled Cryopreserved Human Hepatocytes for P450 Inhibition Study*" (Exhibit E.9).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Inventory Data Sheet – Cryopreserved Human Hepatocytes*" (Exhibit E.10) (*see also* [www.invitrogen.com](http://www.invitrogen.com)).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Inventory Data Sheet – Pooled Cryopreserved Human Hepatocytes*" (Exhibit E.11) (*see also* [www.invitrogen.com](http://www.invitrogen.com)).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Accelerating the Discovery and Development of Safe and Effective Drugs*" (Exhibit E.13).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Inventory Data Sheet – Cryopreserved Animal Hepatocytes*" (Exhibit E.15) (*see also* [www.invitrogen.com](http://www.invitrogen.com)).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Cryopreserved Hepatocytes*" (Exhibit E.16) (*see also* [www.invitrogen.com](http://www.invitrogen.com)).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Hepatocytes – Human.*" (*see also* [www.invitrogen.com](http://www.invitrogen.com)).

Screen Shot from [www.cellzdirect.com](http://www.cellzdirect.com); "*Hepatocytes – Human.*" (*see also* [www.invitrogen.com](http://www.invitrogen.com)).

Lawrence *et al.*, "*Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture*," 5(1) *Toxicology In Vitro* 39-51 (1991).

Lee *et al.*, "*Hepatocyte Transplantation: State Of The Art And Strategies For Overcoming Existing Hurdles*," 3(2) *Annals of Hepatology* 48-53 (2004).

Lemaigre *et al.*, "*Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis*," 14(5) *Current Opinions in Genetics & Development* 582-590 (2004).

Li *et al.*, “*Isolation And Culturing Of Hepatocytes From Human Liver*,” 14 *Journal of Tissue Culture Methods* 139-146 (1992).

Li *et al.*, “*Cryopreserved Human Hepatocytes: Characterization Of Drug-Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability, And Drug-Drug Interaction Potential*,” 121(1) *Chemico-Biological Interactions* 17-35 (1999).

Li *et al.*, “*Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel*,” 121(1) *Chemico-Biological Interactions* 117-123 (1999).

Lloyd *et al.*, “*Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking*,” 4 *Cell and Tissue Culture Banking* 3-15 (2003).

Loretz *et al.*, “*Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes*,” 19(5) *Xenobiotica*. 489-498 (1989).

Madan *et al.*, “*Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes*,” 27(3) *Drug Metabolism and Disposition*. 327-335 (1999).

Meng *et al.*, “*Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics*,” 26(18) *Biotechnology Letters* 1407-1412 (2004).

Morsiani *et al.*, “*Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes*,” 41 *ASAIO Journal* 155-161 (1995).

Nanji “*Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis*,” 8(3) *Clinics in Liver Disease* 559-574 (2004).

Novicki *et al.*, “*Cryopreservation Of Isolated Rat Hepatocytes*,” 18(4) *In Vitro* 393-399 (1982).

O'Brien *et al.*, “*The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study*,” (undated).

Ponsoda *et al.*, “*Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?*” 32(2) *Alternatives to Laboratory Animals*. 101-110 (2004).

Postic *et al.*, “*Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis*,” 30(5) *Diabetes Metabolism* 398-408 (2004).

Roymans *et al.*, “*Determination Of Cytochrome P450 1A2 And Cytochrome P4503a4 Induction In Cryopreserved Human Hepatocytes*,” 67(3) *Biochemical Pharmacology* 427-437 (2004).

Ruegg *et al.*, “*Cytochrome-P450 Induction and Conjugated Metabolism In Primary Human Hepatocytes After Cryopreservation*,” 10 *In Vitro Toxicology* 217-222 (1997).

Seglen “*Preparation Of Isolated Rat Liver Cells*,” 13 *Methods in Cell Biology* 29-83 (1976).

Sekido *et al.*, "Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure," 36(8) Transplantation Proceedings 2355-2356 (2004).

Shaddock *et al.*, "Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis," 9(4) Cell Biology and Toxicology 345-357 (1993).

Silva *et al.*, "Induction Of Cytochrome-P450 In Cryopreserved Rat And Human Hepatocytes," 121 Chemico-Biological Interactions 49-63 (1999).

Sun *et al.*, "Cryopreservation Of Cynomologus Monkey (*Macaca fascicularis*) Hepatocytes For Subsequent Culture And Protein Synthesis Studies," 25 In Vitro Cell Development and Biology 147-150 (1990).

Utesch *et al.*, "Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes," 44 Biochemical Pharmacology 309-315 (1992).

Zaleski *et al.*, "Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen," 46(1) Biochemical Pharmacology 111-116 (1993).

Zhang *et al.*, "Validation of Pooled Cryopreserved Human Hepatocytes as a Model for Metabolism Studies," [www. bdbiosciences.com](http://www.bdbiosciences.com) (undated).

Li, "Overview: hepatocytes and cryopreservation--a personal historical perspective," 121 Chemico-Biological Interactions 1-5 (1999).

U.S. Patent No. 5,795,711

U.S. Patent No. 5,895,745

U.S. Patent No. 6,136,525

U.S. Patent No. 6,759,245

U.S. Publication No. 2002/0039786

U.S. Publication No. 2003/0134418

EP 0834252

WO 92/12722

WO /0153462

WO 03/105663

WO 2004/009766

WO 2005/000376

Terry *et al.*, "Cryopreservation of isolated human hepatocytes for transplantation: State of the art," 53 Cryobiology 149-159 (2006).

Screen Shot from [www.bdbiosciences.com](http://www.bdbiosciences.com); "Hepatocytes"

Screen Shot from [www.xenotechil.com](http://www.xenotechil.com); "Cryopreserved Hepatocytes"

Zaleski et al., "*Maintenance of Key Metabolic Properties of Freshly Isolated Hepatocytes by Cryopreservation in Liquid Nitrogen*," 7(3) In Vitro Toxicology 253-258 (1994).

## **EXHIBIT C**



US007604929B2

(12) **United States Patent**  
**Dryden et al.**

(10) **Patent No.:** **US 7,604,929 B2**  
(45) **Date of Patent:** **Oct. 20, 2009**

(54) **CELLULAR COMPOSITIONS AND METHODS FOR THEIR PREPARATION**

(75) Inventors: **Daniel Dryden**, Westminter, MD (US);  
**James Hardy**, Ijamsville, MD (US)

(73) Assignee: **In Vitro Technologies, Inc.**, Baltimore, MD (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 318 days.

(21) Appl. No.: **11/110,879**

(22) Filed: **Apr. 21, 2005**

(65) **Prior Publication Data**

US 2005/0239042 A1 Oct. 27, 2005

(51) **Int. Cl.**

**A01N 1/00** (2006.01)

**C12N 5/00** (2006.01)

**C12N 5/08** (2006.01)

(52) **U.S. Cl.** ..... **435/1.1; 435/1.3; 435/370; 435/374; 435/375**

(58) **Field of Classification Search** ..... **435/1.1, 435/1.3, 370, 374, 375**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,795,711 A 8/1998 Mullon et al.  
5,895,745 A 4/1999 Chandler et al.  
6,136,525 A 10/2000 Mullon et al.  
6,759,245 B1 7/2004 Toner et al.  
2002/0039786 A1 4/2002 Reid et al.  
2003/0134418 A1 7/2003 Mitaka

**FOREIGN PATENT DOCUMENTS**

EP 0834252 B 4/1998  
WO WO92/12722 8/1992  
WO WO/0153462 7/2001  
WO WO03/105663 12/2003  
WO WO2004/009766 1/2004  
WO WO2005/000376 1/2005

**OTHER PUBLICATIONS**

Ostrowska et al., Cell and Tissue Banking, 2000, 1: 55-68.\*  
Shibata et al., Drug Metabolism and Disposition, 2002, 30: 892-896.\*  
Oehninger et al., Mol Cell Endocrinol, 2000, 169: 3-10.\*  
Hengstler et al., Drug Metab. Rev., 2000, 32: 81-118, Abstract.\*  
Arikura et al., UW solution: a promising tool for cryopreservation of primarily isolated rat hepatocytes, 9 J. Hepatobiliary Pancreat. Surg. 742-749 (2002).  
Marsh et al., Hypothermic Preservation of Hepatocytes III Effects of Resuspension Media on Viability after up to 7 Days of Storage, 13(3) Hepatology 500-508 (1991).  
Smrzova et al., Optimisation of Porcine Hepatocyte Cryopreservation by Comparison of Viability and Enzymatic Activity of Fresh and Cryopreserved Cells, 70 Acta Vet. Bmo. 141-147 (2001).  
Vincent et al., Adjustment of the Osmolality of Percoll for the Isopycnic Separation of Cells and Cell Organelles, 141 Analytical Biochemistry 322-328 (1984).

Adams, R.M. et al. (1995) "Effective Cryopreservation And Long-Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential," Cell Transplant. 4(6):579-586.  
Alexandre, E. et al. (2002) "Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies," Cryobiology 44:103-113.  
Anand, A.C. (1996) "Bioartificial Livers: The State Of The Art," Trop Gastroenterol. 17(4):197-198, 202-211.  
Berry, M.N. et al. (1992) "Techniques for Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions," Life Sci. 51(1):1-16.  
Burlina, A.B. (2004) "Hepatocyte Transplantation For Inborn Errors Of Metabolism," J. Inher. Metab. Dis. 27(3):373-83.  
Chan, C. et al. (2004) "Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies," Liver Transpl. 10(11):1331-1342.  
Chesno, C. et al. (1993) "Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation," Hepatology 18(2):406-414.  
Counlouris, J.A. et al. (1993) "Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies," Xenobiotica. 23(12):1399-1409.  
Diener, B. et al. (1993) "A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics," Cryobiology 30(2):116-127.  
Dou, M. et al. (1992) "Thawed Human Hepatocytes In Primary Culture," Cryobiology 29(4):454-69.  
Fox, L.J. et al. (2004) "Hepatocyte Transplantation," Am. J. Transplant 4 Suppl. 6:7-13.  
Fukuda, J. et al. (2004) "Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver," Int J Artif Organs. 27(12):1091-1099.  
Gan, J.H. et al. (2005) "Hybrid Artificial Liver Support System For Treatment Of Severe Liver Failure," World J Gastroenterol. 11(6):890-894.  
Gomez-Lechon, M.J. et al. (2004) "Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism In Man," Curr Drug Metab. 5(5):443-462.  
Guillouzo, A. et al. (1986) "Isolated and Cultured Hepatocytes," Paris: les Editions INSERM and London: John Libbey Eurotext).  
Hewitt, N.J. et al. (2004) Cryopreserved Rat, Dog and Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures, Hum Exp Toxicol. 23(6):307-316.  
Horslen, S.P. (2004) "Hepatocyte Transplantation," Transplantation 77(10):1481-1486.  
Houle, C. et al. (2003) "Retention Of Transporter Activities In Cryopreserved, Isolated Rat Hepatocytes," Drug Metab. Dispos. 31(4):447-451.  
Kasai, S. et al. (1993) "Large Scale Cryopreservation Of Isolated Dog Hepatocytes," Cryobiology 30:1-11.

(Continued)

Primary Examiner—Ileana Popa  
(74) Attorney, Agent, or Firm—Loeb & Loeb LLP

(57) **ABSTRACT**

The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.

**11 Claims, No Drawings**

## US 7,604,929 B2

Page 2

## OTHER PUBLICATIONS

- Lawrence, J.N. et al. (1991) "Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture," *Toxicology In Vitro*, 5(1):39-51.
- Lee, S. W. et al. (2004) "Hepatocyte Transplantation: State Of The Art And Strategies For Overcoming Existing Hurdles," *Ann. Hepatol.* 3(2):48-53.
- Lemaigre, F. et al. (2004) "Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis," *Curr Opin Genet Dev.* 14(5):582-590.
- Li, A.P. et al. (1992) "Isolation And Culturing Of Hepatocytes From Human Liver," *J. Tissue Cult. Meth.* 14:139-146.
- Li, A.P. et al. (1999) "Cryopreserved Human Hepatocytes: Characterization Of Drug-Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability, And Drug-Drug Interaction Potential," *Chem Biol Interact.* 121(1):17-35.
- Li, A.P. et al. (1999) "Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel," *Chem Biol Interact.* 121(1):117-123.
- Lloyd, T.D.R. et al. (2003) *Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking, Cell And Tissue Culture Banking* 4:3-15.
- Loretz, L.J. et al. (1989) "Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes," *Xenobiotics.* 19(5):489-498.
- Madan, A. et al. (1999) "Effect Of Cryopreservation On Cytochrome P-450 Enzyme Induction In Cultured Rat Hepatocytes," *Drug Metab. Dispos.* 27(3):327-335.
- Meng, Q. et al. (2004) "Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics," *Biotechnol Lett.* 26(18):1407-1412.
- Morsiani et al., (1995) "Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes," *ASAIO Journal* 41:155-161.
- Nanji, A.A. (2004) "Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis," *Clin Liver Dis.* 8(3):559-574.
- Novicki, D.L. et al. (1982) "Cryopreservation Of Isolated Rat Hepatocytes," *In Vitro.* 18(4):393-399.
- O'Brien, Z.Z. et al. (undated) "The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study,"
- Ponsoda, X. et al. (2004) "Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?" *Altern Lab Anim.* 32(2): 101-110.
- Postic, C. et al. (2004) "Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis," *Diabetes Metab.* 30(5):398-408.
- Roymans, D. et al. (2004) "Determination Of Cytochrome P450 1A2 And Cytochrome P4503a4 Induction In Cryopreserved Human Hepatocytes," *Biochem Pharmacol.* 67(3):427-437.
- Ruegg, C.E. et al. (1997) "Cytochrome-P450 Induction and Conjugated Metabolism In Primary Human Hepatocytes After Cryopreservation," *In Vitro Toxicol.* 10:217-222.
- Seglen, P.O. (1976) "Preparation Of Isolated Rat Liver Cells," *Meth. Cell Biol.* 13:29-83.
- Sekido, H. et al. (2004) "Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure," *Transplant Proc.* 36(8):2355-2356.
- Shaddock, J.G. et al. (1993) "Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis," *Cell Biol Toxicol.* 9(4):345-357.
- Silva, J.M. et al. (1999) "Induction Of Cytochrome-P450 In Cryopreserved Rat And Human Hepatocytes," *Chem-Biol Interact* 121:49-63.
- Sun, E.L. et al. (1990) "Cryopreservation Of Cynomolgus Monkey (*Macaca fascicularis*) Hepatocytes For Subsequent Culture And Protein Synthesis Studies," *In vitro Cell Development and Biology* 25:147-150.
- Utesch, D. et al. (1992) "Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes," *Biochemical Pharmacology* 44:309-315.
- Zaleski, J. et al. (1993) "Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen," *Biochem Pharmacol.* 46(1):111-116.
- Zhang, J.G. et al. (undated) "Validation of Pooled Cryopreserved Human Hepatocytes as a Model for Metabolism Studies" [www. Bdhsiences.com](http://www.Bdhsiences.com).
- Li et al., Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics . . . , 121 *Chemico-Biological Interactions* 117-123 (1999).
- Li, Overview: hepatocytes and cryopreservation—a personal historical perspective, 121 *Chemico-Biological Interactions* 1-5 (1999).

\* cited by examiner

US 7,604,929 B2

1

CELLULAR COMPOSITIONS AND  
METHODS FOR THEIR PREPARATION

## FIELD OF THE INVENTION

The present invention relates to novel cell (e.g., hepatocyte, etc.) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of such cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.

## BACKGROUND OF THE INVENTION

Hepatocytes are parenchymal liver cells, and make up 60-80% of the cytoplasmic mass of the liver. Hepatocytes play a key role in the detoxification, modification and excretion of exogenous and endogenous substances (Ponsoda, X. et al. (2004) "Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?" *Altern Lab Anim.* 32(2): 101-110). One of the detoxifying functions of hepatocytes is to modify ammonia to urea for excretion. They are also important in protein synthesis and storage, in the transformation of carbohydrates and in the synthesis of cholesterol, bile salts and phospholipids (Postic, C. et al. (2004) "Role Of The Liver In The Control Of Carbohydrate And Lipid Homeostasis," *Diabetes Metab.* 30(5):398-408). The hepatocyte is the only cell in the body that manufactures albumin, fibrinogen, and the prothrombin group of clotting factors. It is the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, and glycoproteins. Hepatocytes manufacture their own structural proteins and intracellular enzymes. Hepatocytes are also important depots for vitamin B12 and iron.

Due to these attributes, isolated and cultured hepatocytes have become very attractive as models systems for the study of liver functions (Chesne, C. et al. (1993) "Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation," *Hepatology* 18(2):406-414; Guillouzo, A. et al. (1986) "Isolated And Cultured Hepatocytes," Paris: les Editions INSERM and London: John Libbey Eurotext); Ponsoda, X. et al. (2004) "Drug Metabolism By Cultured Human Hepatocytes: How Far Are We From The In Vivo Reality?" *Altern Lab Anim.* 32(2): 101-110; Gomez-Lechon, M. J. et al. (2004) "Human Hepatocytes In Primary Culture: The Choice To Investigate Drug Metabolism In Man," *Curr Drug Metab.* 5(5):443-462; Lemaigre, P. et al. (2004) "Liver Development Update: New Embryo Models, Cell Lineage Control, And Morphogenesis," *Curr Opin Genet Dev.* 14(5):582-590; Nanji, A. A. (2004) "Animal Models Of Nonalcoholic Fatty Liver Disease And Steatohepatitis," *Clin Liver Dis.* 8(3):559-574; Hewitt, N. J. et al. (2004) "Cryopreserved Rat, Dog And Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures," *Hum Exp Toxicol.* 23(6):307-316).

In addition to their use in liver models, hepatocytes have the potential of being used to produce Bioartificial Livers (BALs) or in hepatocyte transplantation that can provide liver functions for individuals suffering from liver disease or liver failure. Bioartificial Livers (BALs) are described by Anand, A. C. (1996) "Bioartificial Livers: The State Of The Art," *Trop Gastroenterol.* 17(4):197-198, 202-211; Gan, J. H. et al. (2005) "Hybrid Artificial Liver Support System For Treatment Of Severe Liver Failure," *World J Gastroenterol.* 11 (6):890-

2

894; Fukuda, J. et al. (2004) "Hepatocyte Organoid Culture In Elliptic Hollow Fibers To Develop A Hybrid Artificial Liver," *Int J Artif Organs.* 27(12): 1091-1099; Meng, Q. et al. (2004) "Hepatocyte Culture In Bioartificial Livers With Different Membrane Characteristics," *Biotechnol Lett.* 26(18): 1407-1412; Sekido, H. et al. (2004) "Usefulness Of Artificial Liver Support For Pretransplant Patients With Fulminant Hepatic Failure," *Transplant Proc.* 36(8):2355-2356; WO03/105663A2, WO05/000376A2, and U.S. Pat. No. 6,759,245. Hepatocyte transplantation is described by Chan, C. et al. (2004) "Hepatic Tissue Engineering For Adjunct And Temporary Liver Support: Critical Technologies," *Liver Transpl.* 10(11): 1331-1342; Lee, S. W. et al. (2004) "Hepatocyte Transplantation: State Of The Art And Strategies For Over-

coming Existing Hurdles," *Ann. Hepatol.* 3(2):48-53; Horslen, S. P. (2004) "Hepatocyte Transplantation," *Transplantation* 77(10):1481-1486; Burlina, A. B. (2004) "Hepatocyte Transplantation For Inborn Errors Of Metabolism," *J. Inher. Metab. Dis.* 27(3):373-83; and Fox, I. J. et al. (2004) "Hepatocyte Transplantation," *Am. J. Transplant.* 4 Suppl. 6:7-13. A limiting factor in the development of such model systems and to the development of Bioartificial Livers (BALs) has been the erratic source and limited availability of hepatocytes, especially human hepatocytes. Fresh hepatocytes are obtainable only from liver resections or non-transplantable livers of multi-organ donors (Lloyd, T. D. R. et al. (2003) "Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking," *Cell and Tissue Culture Banking* 4:3-15). The supply of such tissue is inconsistent and often geographically inconvenient in light of the limited functional lifespan of liver tissue (Senzova, J. et al. (2001) "Optimization Of Porcine Hepatocytes Cryopreservation By Comparison Of Viability And Enzymatic Activity Of Fresh And Cryopreserved Cells," *Acta Veterinaria Brunensis* 70:141-147).

One approach to addressing this problem has involved the development of hepatocyte storage conditions that allow hepatocytes to be maintained over time with their cellular functions preserved. Cryopreservation methods for the storage of hepatocytes have been developed to address this need (see, Lloyd, T. D. R. et al. (2003) "Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking," *Cell and Tissue Culture Banking* 4:3-15; Loretz, L. J. et al. (1989) "Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes," *Xenobiotica.* 19(5):489-498; Shaddock, J. G. et al. (1993) "Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis," *Cell Biol Toxicol.* 9(4):345-357; Novicki, D. L. et al. (1982) "Cryopreservation Of Isolated Rat Hepatocytes," *In Vitro.* 18(4):393-399; Zaleski, J. et al. (1993) "Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen," *Biochem Pharmacol.* 46(1):111-116). Typically, such measures comprise storage in liquid nitrogen (-196° C.) or in frozen nitrogen gas (-150° C.). The ability to recover viable thawed cells has been found to depend on multiple factors such as the rate of freezing, the concentration of hepatocytes, the type of cryoprotectant employed, and the final cooling temperature. Cell concentrations of 10<sup>5</sup>-10<sup>7</sup> cells/ml have been typically employed. The isolated hepatocytes are typically incubated in suspension for a period (e.g., 4-48 hours) to allow them to recover from the isolation process. Thereafter, a cryoprotectant (such as glycerol, DMSO, polyvinylpyrrolidone, or dextran) is added, and the hepatocytes are frozen. The art has developed various freezing procedures, all designed to minimize or prevent the occurrence of intracellular ice. The

US 7,604,929 B2

3

freezing rates typically vary from  $-0.05^{\circ}\text{C}/\text{min}$  to  $-50^{\circ}\text{C}/\text{min}$  (see, Lloyd, T. D. R. et al. (2003) *Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking, Cell and Tissue Culture Banking* 4:3-15).

While the development of cryopreservation methods for the storage of hepatocytes has significantly facilitated the availability of human hepatocytes, cryopreservation has been found to cause a significant decrease in cellular viability (e.g., 25-35%) (Dou, M. et al. (1992) "Thawed Human Hepatocytes In Primary Culture," *Cryobiology* 29:454-469; Alexandre, E. et al. (2002) "Cryopreservation Of Adult Human Hepatocytes Obtained From Resected Liver Biopsies," *Cryobiology* 44:103-113). Coundouris, J. A. et al. (1993) reported viability of 67% after 24 hours, declining to 49% after 14 days (Coundouris, J. A. et al. (1993) "Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies," *Xenobiotica* 23(12):1399-1409). Adams, R. M. et al. have reported that the viability of hepatocytes may be enhanced to greater than 90% using specialized cryopreservation fluids, however, only 16% of cells were found to be capable of replication (Adams, R. M. et al. (1995) "Effective Cryopreservation And Long-Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential," *Cell Transplant.* 4(6):579-586). Methods of cryopreservation are disclosed in U.S. Pat. Nos. 5,795,711, 6,136,525, 5,895,745; International Patent Publications WO04/009766, WO92/12722, WO/0153462, European Patent No. EP0834252B, and U.S. Patent Application Publication Nos. US20020039786A1, US20030134418A1. The poor recovery of cells when cryopreserved continues to limit the use of hepatocytes in in vitro liver models.

A second major problem affecting the use of both fresh and cryopreserved hepatocytes is the variation of liver enzyme expression that is observed in tissue from different donors (Li, A. P. et al. (1999) "Present Status Of The Application Of Cryopreserved Hepatocytes In The Evaluation Of Xenobiotics: Consensus Of An International Expert Panel," *Chem Biol Interact.* 121(1):117-123; Li, A. P. et al. (1999) "Cryopreserved Human Hepatocytes: Characterization Of Drug-Metabolizing Enzyme Activities And Applications In Higher Throughput Screening Assays For Hepatotoxicity, Metabolic Stability And Drug-Drug Interaction Potential," *Chem Biol Interact.* 121(1):17-35; O'Brien, Z. Z. et al. (undated) "The Construction Of A Representative Human Cryopreserved Hepatocyte Pool For Metabolism Study." One solution to this sample variation involves pooling samples from different sources to produce a "composite" hepatocyte preparation having the characteristics of "average" liver cells. However, the frequency of receipt of fresh tissue and the need to cryopreserve hepatocytes immediately after isolation has been cited as preventing the preparation of hepatocyte pools. Thus, multiple companies (e.g., Xenotech, LLC; BD Biosciences) refrain from selling pooled hepatocytes thus forcing the end user to thaw and pool hepatocytes from several different donors. This difficulty remains even though pooled cryopreserved human hepatocytes are a valid model for metabolic studies (Zhang, J. G. et al. (undated) "Validation Of Pooled Cryopreserved Human Hepatocytes As A Model For Metabolic Studies."

Thus, despite all prior advances, a need remains for processes that would enable the availability of hepatocytes for medical research and other purposes. A need further exists for a stable and reproducible source of human hepatocytes. The present invention permits the production and availability of hepatocyte preparations that may be repeatedly cryopreserved and thawed without unacceptable loss of viability. The

4

invention thus permits multiple hepatocyte samples to be pooled to produce pooled hepatocyte preparations, especially pooled cryopreserved human hepatocyte preparations. Using such advance, pooled cryopreserved human hepatocytes are now commercially available from In Vitro Technologies (Baltimore, Md.).

#### SUMMARY OF THE INVENTION

The present invention relates to novel cell (e.g., hepatocyte) compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been repeatedly cryopreserved and thawed.

In detail, the invention particularly concerns a multi-cryopreserved hepatocyte preparation comprising hepatocytes that have been frozen and thawed at least two times, wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.

The invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.

The invention further concerns the embodiment of such a multi-cryopreserved hepatocyte preparation wherein the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).

The invention further concerns a method of producing a desired preparation of multi-cryopreserved hepatocytes, the hepatocytes being capable of being frozen and thawed at least two times, and in which greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable, the method comprising:

- (A) subjecting hepatocytes that have been frozen and thawed to density gradient fractionation (especially percoll density centrifugation) to separate viable hepatocytes from non-viable hepatocytes,
- (B) recovering the separated viable hepatocytes, and
- (C) cryopreserving the recovered viable hepatocytes to thereby form the desired preparation of hepatocytes.

The invention further concerns the embodiment of such a method in which the hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.

The invention further concerns the embodiment of such a method in which the preparation comprises a pooled preparation of hepatocytes of multiple sources, which may be of the same or different gender, race, or health state, or which provide the pooled preparation with a desired level of a metabolic activity (especially wherein the metabolic activity is selected from the group consisting of COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, PHEN and CZX).

The invention also concerns a method of investigating in vitro drug metabolism comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence

US 7,604,929 B2

5

of a xenobiotic, and determining the metabolic fate of the xenobiotic, or the effect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof, wherein the hepatocytes have been frozen and thawed at least two times, and wherein greater than 50% and more preferably 70% or more of the hepatocytes of the preparation are viable.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining substantial viability. The methods of the present invention are generally applicable to a wide variety of cell types, including hepatocytes, kidney cells, spleen cells, thymus cells, bone marrow cells, stem cells, muscle cells (including cardiac muscle cells), endocrine cells (including pancreatic cells, adrenal cells, thyroid cells, etc.) epidermal cells, endodermal cells, etc. The methods of the present invention are illustrated below with respect to a preferred cell type: hepatocytes.

The invention also concerns preparations of cells, e.g., hepatocytes, that have been repeatedly cryopreserved and thawed to obtain a high viability preparation useful for a variety of experimental, diagnostic and therapeutic purposes. The present invention extends the ability of hepatocytes to be cryopreserved and thawed for later use, so as to permit hepatocyte preparations to be repeatedly cryopreserved and thawed without an unacceptable loss of viability.

As used herein, the term "cell preparation" denotes a liquid or frozen composition of cells from one or more sources (e.g., "hepatocyte preparation" denotes a composition of liver cells from one or more sources). The sources may be primary cells that have been dissociated from or isolated from tissue as by resection, biopsy, or from donor organs, or they may be secondary, immortalized or transformed cell cultures. The cells may be derived from any mammalian source, including human, porcine, simian, canine, feline, bovine, equine, ovine or rodent sources. The use of human, porcine or rodent (especially rat) cells is preferred. Preferably, greater than 50% and more preferably 70% or more of the hepatocytes of such preparations will be viable.

As used herein, the term "multi-cryopreserved cell preparation" denotes a cell preparation that has been frozen and then thawed at least two times (e.g., a "multi-cryopreserved hepatocyte preparation" denotes a hepatocyte preparation that has been frozen and then thawed at least two times). Such preparations may have been frozen and thawed three, four, five, or more times.

The term "pooled preparation" denotes a cell (e.g., hepatocyte) preparation in which the cells (e.g., hepatocytes) are derived from two, three, four, five, or more different sources, such as different donors, biopsies, tissue resections from different tissue samples or different tissue sources, or different primary, secondary, immortalized or transformed cell (e.g., hepatocyte) cultures. The cells of such pooled preparations may be randomly selected cell, or may have been selected to provide the pooled preparation with a desired level of one or more metabolic activities (such as for example, a preparation of hepatocytes having a desired level of COUM, DEX, BCOD, 7-HCG, 7-HCS, MEPI, TEST, PHEN and/or CZX activity), or a desired cell characteristic (such as, for example, a preparation of hepatocytes derived from sources of the same gender, age, race (e.g., Caucasian, etc.), or health state (e.g., hepatocytes of hepatitis virus-infected liver, hepatocytes of

6

HIV-1 infected liver, hepatocytes of healthy liver, hepatocytes of cigarette smokers, hepatocytes of individuals suffering from cirrhosis of the liver, or from other diseases or conditions). For example, to obtain a pooled hepatocyte preparation with minimal DEX activity, a pooled preparation could be prepared from Lot Nos. 067, CEK, ETR, PFM, VTA, or WWM (see, Table III).

In a preferred embodiment, illustrated with respect to hepatocyte cells, the practice of the invention comprises some or all of the following steps: the isolation of hepatocytes, a first cryopreservation of the isolated primary hepatocytes to obtain a first cryopreserved hepatocyte preparation, the thawing of the first cryopreserved hepatocyte preparation to obtain viable hepatocytes, and the reformulation of the thawed viable hepatocytes to permit their further storage and use through repeated cryopreservation and thawing to obtain viable hepatocytes.

#### The Isolation of Hepatocytes

Any of a wide variety of methods may be employed or adapted to permit the isolation of the primary hepatocytes used in the present invention. For example, suitable techniques for the isolation of hepatocytes are outlined in Morsiani et al., (1995) "Automated Liver Cell Processing Facilitates Large Scale Isolation And Purification Of Porcine Hepatocytes," *ASAIO Journal* 41:155-161 and in Seglen, P. O. (1976) "Preparation Of Isolated Rat Liver Cells," *Meth. Cell Biol.* 13:29-83). Specific reference is made to the two-step collagenase digestion procedure described in Li, A. P. et al. (1992) "Isolation And Culturing Of Hepatocytes From Human Liver," *J. Tissue Cult. Meth.* 14:139-146.

The hepatocytes may be cultured in any suitable hepatocyte culture medium. By way of illustration and not limitation mention may be made of the following culture media: Chee's Essential Media (Hamilton, G. A. et al. (2001) "Effects Of Medium Composition On The Morphology And Function Of Rat Hepatocytes Cultured As Spheroids And Monolayers," *In Vitro Cell Dev Biol Anim.* 37(10):656-667; Zurlo, J. et al. (1996) "Characterization Of A Primary Hepatocyte Culture System For Toxicological Studies," *In Vitro Cell Dev Biol Anim.* 32(4):211-220; Arterburn, L. M. et al. (1995) "A Morphological Study Of Differentiated Hepatocytes In Vitro," *Hepatology* 22(1):175-187), Modified Eagle Medium (or Dulbecco's Modified Eagle Medium) (Arikura, J. et al. (2002) "UW Solution: A Promising Tool For Cryopreservation Of Primarily Isolated Rat Hepatocytes," *J Hepatobiliary Pancreat Surg.* 9(6):742-749; Washizu, J. et al. (2000) "Amino Acid Supplementation Improves Cell-Specific Functions Of The Rat Hepatocytes Exposed To Human Plasma," *Tissue Eng.* 6(5):497-504; Iwata, H. et al. (1999) "In Vitro Evaluation Of Metabolic Functions Of A Bioartificial Liver," *ASAIO J.* 45(4):299-306; Stutenkemper, R. et al. (1992) "The Hepatocyte-Specific Phenotype Of Murine Liver Cells Correlates With High Expression Of Connexin32 And Connexin26 But Very Low Expression Of Connexin43," *Exp Cell Res.* 201(1):43-54), Leibowitz medium (Coundouris, J. A. et al. (1993) "Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies," *Xenobiotica.* 23(12):1399-1409), Waymouth (Vind, C. et al. (1992) "Regulation By Growth Hormone And Glucocorticoid Of Testosterone Metabolism In Long-Term Cultures Of Hepatocytes From Male And Female Rats," *Biochem Pharmacol.* 44(8):1523-1528; Nemoto, N. et al. (1991) "Proline Is Required For Transcriptional Control Of The Aromatic Hydrocarbon-Inducible P(1)450 Gene In C57BL/6 Mouse Monolayer-Cultured Hepatocytes," *Jpn J Cancer Res.* 82(8):901-908; Dich, J. et al. (1988) "Long-Term Culture Of Hepatocytes: Effect Of

US 7,604,929 B2

7

*Hormones On Enzyme Activities And Metabolic Capacity*," *Hepatology*, 8(1):39-45; Goethals, F. et al. (1984) "Critical Biochemical Functions Of Isolated Hepatocytes As Sensitive Indicators Of Chemical Toxicity," *Fundam Appl Toxicol.* 4(3 Pt 1):441-450; Kreb's medium (House, J. D. (2001) "Threonine Metabolism In Isolated Rat Hepatocytes," *Am J Physiol Endocrinol Metab.* 281(6):E1300-1307; Irvine, F. et al. (1993) "Extracellular Calcium Modulates Insulin's Action On Enzymes Controlling Cyclic AMP Metabolism In Intact Hepatocytes," *Biochem J.* 293 (Pt 1):249-253; Marsh, D. C. et al. (1991) "Hypothermic Preservation Of Hepatocytes. III. Effects Of Resuspension Media On Viability After Up To 7 Days Of Storage," *Hepatology* 13(3):500-508, etc.

In a preferred embodiment, hepatocytes are cryopreserved in a medium containing approximately 10% DMSO and approximately 90% fetal bovine serum (Loretz, L. J. et al. (1989) "Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes," *Xenobiotica* 19:489-498; Ruegg, C. E. et al. (1997) "Cytochrome-P450 Induction and Conjugated Metabolism In Primary Human Hepatocytes After Cryopreservation," *In Vitro Toxicol.* 10:217-222).

The viability of the isolated hepatocytes may be determined using any of a variety of methods. Preferable, such viability will be determined using the Trypan blue exclusion method (see, e.g., Berry, M. N. et al. (1992) "Techniques For Pharmacological And Toxicological Studies With Isolated Hepatocyte Suspensions," *Life Sci.* 51(1):1-16). Thus the phrases "viable hepatocytes" or "percent viability", as used herein, refers to hepatocyte viability as assessed using the method of Trypan Blue exclusion.

#### Cryopreservation of the Isolated Primary Hepatocytes

The hepatocytes of the present invention are preferably cryopreserved using liquid nitrogen, and most preferably within 36 hours of their isolation. Considerations for the cryopreservation of human hepatocytes are discussed in Lloyd, T. D. R. et al. (2003) *Cryopreservation Of Hepatocytes: A Review Of Current Methods For Banking*, "Cell and Tissue Culture Banking" 4:3-15. Suitable procedures for the cryopreservation of hepatocytes may also be found in the following documents: Adams, R. M. et al. (1995) "Effective Cryopreservation And Long-Term Storage Of Primary Human Hepatocytes With Recovery Of Viability, Differentiation, And Replicative Potential," *Cell Transplant.* 4(6):579-586; Chesne, C. et al. (1993) "Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation," *Hepatology* 18(2):406-414; Coundouris, J. A. et al. (1993) "Cryopreservation Of Human Adult Hepatocytes For Use In Drug Metabolism And Toxicity Studies," *Xenobiotica*, 23(12): 1399-1409; Hewitt, N. J. et al. (2004) *Cryopreserved Rat, Dog And Monkey Hepatocytes: Measurement Of Drug Metabolizing Enzymes In Suspensions And Cultures*, "Hum Exp Toxicol." 23(6):307-316; Novicki, D. L. et al. (1982) "Cryopreservation Of Isolated Rat Hepatocytes," *In Vitro*, 18(4):393-399; Shaddock, J. G. et al. (1993) "Cryopreservation And Long-Term Storage Of Primary Rat Hepatocytes: Effects On Substrate-Specific Cytochrome P450-Dependent Activities And Unscheduled DNA Synthesis," *Cell Biol Toxicol.* 9(4):345-357; Zaleski, J. et al. (1993) "Preservation Of The Rate And Profile Of Xenobiotic Metabolism In Rat Hepatocytes Stored In Liquid Nitrogen," *Biochem Pharmacol.* 46(1):111-116.

Preferably, isolated hepatocytes are suspended in a cryoprotective medium, and the suspended cells are dispensed into freezer-safe containers. A cryoprotective medium typically comprises a hepatocyte culture medium that contains at

8

least one cryoprotectant that minimizes the deleterious effects of cryopreservation such as the formation of intracellular ice during freezing. By way of illustration and not limitation, the following commonly used cryoprotectants are listed: dimethylsulfoxide (DMSO), polyethylene glycol, amino acids, propanediol, and glycerol. A preferred cryoprotectant of the present invention is DMSO. Suitable cryoprotectants and methods for their use in hepatocyte cryopreservation can be found, for example, in: Loretz, L. J. et al. (1989) "Optimization Of Cryopreservation Procedures For Rat And Human Hepatocytes," *Xenobiotica*, 19(5):489-498; Chesne, C. et al. (1993) "Viability And Function In Primary Culture Of Adult Hepatocytes From Various Animal Species And Human Beings After Cryopreservation," *Hepatology* 18(2):406-414; Diener, B. et al. (1993) "A Method For The Cryopreservation Of Liver Parenchymal Cells For Studies Of Xenobiotics," *Cryobiology* 30(2):116-127; Lawrence, J. N. et al. (1991) "Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture," *Toxicology In Vitro*, 5(1):39-51; Houle, r. et al. (2003) "Retention of Transporter Activities In Cryopreserved, Isolated Rat Hepatocytes," *Drug Metab. Dispos.* 31(4):447-451; Silva, J. M. et al. (1999) "Induction Of Cytochrome-P450 In Cryopreserved Rat And Human Hepatocytes," *Chem-Biol Interact* 121:49-63.

The isolated hepatocytes are preferably suspended in a cryoprotective medium in preparation for freezing. The suspended cells are preferably dispensed into freezer resistant containers at a cell density of from about  $10^6$  cells/ml to about  $4 \times 10^7$  cells/ml. Preferred freezing volumes range from 0.1-10.0 ml. The preferred freezing volume is 1.0 ml.

The dispensed hepatocytes are then preferably cryopreserved using a controlled rate freezing process, most preferably at a freezing rate of between about  $-1^\circ \text{C}/\text{min}$  to about  $-25^\circ \text{C}/\text{min}$  until a final temperature of about  $-90^\circ \text{C}$ . is reached. During the initial phase of the cryopreservation process, seeding may be employed to induce controlled crystallization or ice formation in cell suspensions that have already been cooled to below the freezing point of the culture medium. Such seeding serves to minimize ice formation-related damage and therefore may be beneficial to cell viability. Suitable seeding methods include inserting a cold metal rod into the freezing containers, and introducing a blast of liquid nitrogen into the freezing containers.

Once the desired final temperature has been reached, the frozen cell samples may be transferred to liquid nitrogen freezers for prolonged storage. The frozen samples may be stored in either the liquid nitrogen phase or the gas phase of liquid nitrogen. Preferably storage is accomplished in the gas phase of liquid nitrogen. The frozen samples may be stored in this manner for days, months, or years, with the length of storage in the gas phase of liquid nitrogen having little effect on the post-thaw viability and function.

#### The Thawing Of Cryopreserved Hepatocytes

Frozen samples may be thawed for further processing by removing them from the presence of liquid nitrogen or liquid nitrogen vapor. Frozen samples are preferably thawed by placing the samples immediately into a prewarmed water bath having a temperature of between about  $37^\circ \text{C}$ . to about  $42^\circ \text{C}$ . Preferably, cells are thawed to at least the stage in which ice chunks can be dislodged when the sample container is inverted. The thawed cells are then preferably rapidly processed to remove the cells from contact with DMSO, for example by PERCOLL<sup>®</sup> (colloidal silica particles of 15-30 nm diameter (23% w/w in water) which have been coated

US 7,604,929 B2

9

with polyvinylpyrrolidone (PVP)) gradient centrifugation (as described below) or by sequential washings.

In a preferred embodiment, the cells are thawed into Complete INVITROGRO™ CP medium (In Vitro Technologies, Baltimore, Md.; Roymans, D. et al. (2004) "Determination Of Cytochrome P450 1A2 And Cytochrome P4503A4 Induction In Cryopreserved Human Hepatocytes," *Biochem Pharmacol.* 67(3):427-437) (hepatocyte plating medium, which contains water, Dulbecco's Modified Eagle Medium, sodium bicarbonate, HEPES, fructose, bovine serum albumin, sodium hydroxide, MEM non-essential amino acids, insulin, hydrocortisone, and newborn calf serum). The medium is prepared by thawing TORPEDO™ Antibiotic Mix (In Vitro Technologies, Baltimore, Md.) (a mixture of antibiotics selected to inhibit bacterial growth in hepatocyte cell cultures that contains penicillin, streptomycin, gentamicin, amikacin and fungizone) to 37° C. in a water bath until thawed, and then removed from the water bath. 1.0 ml of TORPEDO™ Antibiotic Mix is then mixed with 45 ml INVITROGRO™ CP medium. Following the addition of TORPEDO™ Antibiotic Mix, the shelf life for the complete medium is 7 days. When thawing a single vial, the INVITROGRO™ CP medium is prewarmed to approximately 37° C. 5 ml of warmed INVITROGRO™ CP medium is added to a sterile 50 ml conical tube. The vial of frozen hepatocytes is carefully removed from the freezer. If the vial was stored in the liquid phase, its cap is carefully removed, any liquid nitrogen present in the vial is decanted, and the cap is reclosed before placing the vial into the water bath. It is preferred to then immediately immerse the vial into a 37° C. water bath, and to shake the vial gently until the ice is entirely melted, but no longer than it takes to completely thaw the vial. It may be helpful to remove any labels from the vial so that it will be easier to view the vial contents. The thawed contents are then emptied into the prewarmed INVITROGRO™ CP medium. 1.0 ml of prewarmed INVITROGRO™ CP medium then is added to each vial to resuspend any remaining cells. The contents of the vial are then decanted or pipetted into the hepatocyte suspension. The hepatocytes are preferably resuspended by gently inverting the receiving container (e.g., vial, test tube, etc.) several (e.g., three) times.

When thawing multiple vials, it is preferred that all of the vials be thawed in the water bath simultaneously. As before, the medium (preferably, INVITROGRO™ CP medium) should be warmed to 37° C. It is desirable to ensure that there is enough medium to permit 5 ml of pre-warmed INVITROGRO™ CP medium to be used for each vial of cryopreserved hepatocytes. After vials have thawed, their caps should be quickly removed and their contents poured into a sterile tube or beaker that contains at least 5 ml of pre-warmed INVITROGRO™ CP medium per vial thawed. For example, 25 ml of media is preferably employed for 5 vials in a container that can hold a volume of 50 ml.

If desired, the total cell count and the number of viable cells may be determined using the Trypan Blue exclusion method. Cells may be diluted to  $0.70 \times 10^5$  viable cells/ml with INVITROGRO™ CP medium.

#### The Reformulation of Thawed Hepatocytes to Permit Further Cryopreservation and Thawing

One aspect of the present invention concerns the ability to reformulate the thawed cells so that they may be refrozen and rethawed on one or more subsequent occasions. Such multi-cryopreserved hepatocyte preparations have multiple uses. They may be used in bioartificial livers, liver cell transplants, liver assist devices, hepatocyte transplantations, and in vitro applications. In particular, multi-cryopreserved hepatocyte

10

preparations may be used in in vitro drug metabolism studies (for example, in identifying hepatocytes with unique characteristics (e.g., metabolic polymorphisms, genetic polymorphisms, etc.), in studies on the metabolic fate of the xenobiotic and studies on the affect of the xenobiotic in altering the drug-metabolizing enzyme profile of the hepatocytes, in inhibition studies to determine the IC<sub>50</sub> of xenobiotics on liver enzymes and functions (e.g. cholesterol metabolism), in gene induction studies with xenobiotics, in protein induction studies with xenobiotics, in toxicity assessment of xenobiotics on hepatocytes, transport studies with xenobiotics (e.g. studies on P-glycoprotein transport systems, organic ion transporters, organic cation transporters, etc.), in metabolic clearance studies with xenobiotics, and in efficacy assays (e.g. lipoprotein processing, gluconeogenesis, protein secretion etc.). Multi-cryopreserved hepatocyte preparations may also be used to study or propagate hepatitis viruses and other infectious viruses and agents. Recovered cells may be reformulated for use in DNA, mRNA or proteomic studies or in studies of metabolic polymorphisms. Multi-cryopreserved hepatocyte preparations may also be used in metabolic clearance studies and efficacy assays (e.g., lipoprotein processing, gluconeogenesis, protein secretion, etc.). Cells may be reformulated for use in seeding bioreactors for large scale incubations or as models for gene regulation via micro RNA, or for use in combination systems with other cell types (e.g. non-parenchymal cells from liver or cells from other sources, e.g. Caco-2 cells).

In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent refreezing. Density gradient centrifugation is preferably employed for this purpose. For example, a 30% PERCOLL® gradient centrifugation procedure may be employed (Madan, A. et al. (1999) "Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes, *Drug Metab. Dispos.* 27(3):327-335; Sun, E. L. et al. (1990) "Cryopreservation Of Cynomolgus Monkey (*Macaca fascicularis*) Hepatocytes For Subsequent Culture And Protein Synthesis Studies," *In Vitro Cell Development and Biology* 25:147-150; Lawrence, J. N. et al. (1991) "Development Of An Optimal Method For The Cryopreservation Of Hepatocytes And Their Subsequent Monolayer Culture," *Toxicology In Vitro*, 5(1):39-51; Dou, M. et al. (1992) "Thawed Human Hepatocytes In Primary Culture," *Cryobiology* 29(4):454-469; Utesch, D. et al. (1992) "Characterization Of Cryopreserved Rat Liver Parenchymal Cells By Metabolism Of Diagnostic Substrates And Activities Of Related Enzymes," *Biochemical Pharmacology* 44:309-315. For example, the thawed cells may be resuspended in a prewarmed (approximately 37° C.) 30% PERCOLL® isotonic fractionation buffer and then centrifuged at 100xg at room temperature for twenty minutes to pellet viable cells. The supernatant is discarded and the cells are resuspended in media for a subsequent cryopreservation step directly or for further processing prior to cryopreservation.

Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more. Such high viabilities enable the present invention to accomplish the repeated freezing and thawing of hepatocytes without unacceptable losses of cells or the need for ever greater samples sources.

US 7,604,929 B2

11

## Pooled Hepatocyte Preparations

The capacity of the present invention to enable the repeated freezing and thawing of hepatocytes additionally facilitates the production of pooled hepatocyte preparations, especially pooled human hepatocyte preparations. As discussed above, individual liver samples yield hepatocytes having differing metabolic capabilities. In order to facilitate the reproducible use or study of hepatocytes, it is desirable to minimize hepatocyte differences attributable to such sample variation by pooling hepatocytes from different sources to obtain a composite or "average" hepatocyte preparation. Such composite hepatocyte preparations may thus be formulated so as to provide a preparation having the metabolic activities of an "average" hepatocyte sample or a preparation whose hepatocyte enzyme functions approximate the hepatocyte enzyme functions of freshly isolated hepatocytes. Such metabolic activities may include, for example, some or all of the following enzymatic activities: coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycoumarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenytoin 4-hydroxylase (MEPH), testosterone 6( $\beta$ )-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), or chlorzoxazone 6-hydroxylase (CZX). The substrates, methods of measurements and assay units for assays of such metabolic activities are provided in Table I.

12

For example, preferred preparations of pooled hepatocytes will yield assay values within the ranges identified in Table II. Alternatively, the hepatocytes samples used to form the pooled preparation may be selected so as to maximize, minimize, or emphasize certain hepatocyte functions over other functions so as to yield a pooled preparation that exhibits a user desired profile of liver cell function(s).

The pooled hepatocyte preparations of the present invention may comprise hepatocytes obtained from the same source at differing times, or from two or more different sources. Preferably, pooled hepatocyte preparations will result from the pooling of hepatocytes obtained from three, four, five, six or more different sources.

Most preferably, the pooled hepatocyte preparations of the invention will comprise at least one population of hepatocytes that were cryopreserved prior to pooling. For example, a pooled hepatocyte preparation may comprise one or more hepatocyte specimens that were cryopreserved prior to pooling with one or more freshly isolated hepatocyte specimens. Alternatively, a pooled hepatocyte preparation may comprise only hepatocyte specimens that were previously cryopreserved. Table II provides the normal range (i.e., the range between Assay Minimum and Assay Maximum for each Assay). Table II values are derived data of the last 150+ lots of human cryopreserved hepatocytes

TABLE I

## Hepatocyte Metabolic Activities

Abbreviation	Substrate/Assay	Method of Measurement	Units
7-HCG	7-hydroxycoumarin glucuronide	Phase II metabolism of 7-hydroxycoumarin	pmol/min/10 <sup>6</sup> cells
7-HCS	7-hydroxycoumarin sulfate	Phase II metabolism of 7-hydroxycoumarin	pmol/min/10 <sup>6</sup> cells
NAT1	p-aminobenzoic acid	N-acetylation of p-aminobenzoic acid	amol/mg/min
NAT2	Sulfamethazine	N-acetylation of Sulfamethazine	amol/mg/min
VBTY	viability	Trypan Blue™ exclusion	percentage
AP	Alkaline Phosphatase	Sigma kit	units/mg protein
GGT	gamma-glutamyl transpeptidase	GGT stain	positive
UGT1	7-hydroxycoumarin	Phase II metabolism of 7-hydroxycoumarin	169 pmol/mg/min
P450	cytochrome p450 content	carbon monoxide difference spectrum	Not determined for cryo hepatocytes amol/mg protein
CZX	chlorzoxazone	chlorzoxazone 6-hydroxylation	31.1 pmol/mg/min*
COUM	coumarin	coumarin 7-hydroxylation	50.0 pmol/mg/min*
DEX	dextromethorphan	dextromethorphan O-demethylation	21.4 pmol/mg/min*
MEPH	mephenytoin	mephenytoin 4-hydroxylation	24.1 pmol/mg/min*
PHEN	phenacetin	phenacetin O-deethylation	28.9 pmol/mg/min*
TEST	testosterone	testosterone 6(beta)-hydroxylation	96.8 pmol/mg/min*
TOLB	tolbutamide	tolbutamide 4-hydroxylation	30.6 pmol/mg/min*
PROT	protein content	Pierce protein kit	Not determined for cryo hepatocytes mg/mL
ECOD	ethoxycoumarin	7-ethoxycoumarin O-deethylation	37.3 pmol/mg/min*

US 7,604,929 B2

13

TABLE II

Hepatocyte Assays	
Assay	Normal Range (pmol/min/10 <sup>6</sup> cells)
cosmarin 7-hydroxylation	1 to 154
Deoxymethorphan O-demethylation	0.5 to 96
7-ethoxycoumarin O-deethylation	1 to 154
Phase I metabolism of 7-hydroxycoumarin	2 to 545
Phase II metabolism of 7-hydroxycoumarin	0 to 110
mephenytoin 4-hydroxylation	0.2 to 442
testosterone 6(beta)-hydroxylation	2 to 675
tolbutamide 4-hydroxylation	1.8 to 82
phenacetin O-deethylation	1 to 125
chlorzoxazone 4-hydroxylation	2 to 215

In certain embodiments of the invention, hepatocyte preparations will have assay values in the above stated ranges for at least three of, and preferably for at least four of, still more preferably for at least six of, and most preferably for at least eight of the following assays: the COUM assay; the DEX assay; the ECOD assay; the 7-HCG assay; the 7-HCS assay; the MEPI assay; the TEST assay; the TOLB assay; the PHEN assay; the CZX assay.

If desired, the cryopreserved hepatocytes may be plated on to collagen-coated tissue culture plates, or tissue culture plates coated with other extracellular matrix proteins including but not limited to laminin, fibronectin, entactin, poly-L-lysine, gelatin, or any combination thereof. Preferably, this is accomplished by diluting an appropriate volume (e.g., 0.2 ml to 2.5 ml) of diluted cells (e.g., cells having a concentration of approximately  $0.7 \times 10^6$  cells/ml) onto the plates. For plating on a 96-well microtiter plate, it is desirable to further dilute the cell suspension to a concentration of  $0.35 \times 10^6$  cells/ml with InVitroGRO CP medium, and to add 100  $\mu$ l of the cell suspension to each well. It is preferred to even distribute the cells in the wells. This can be accomplished by gently shaking the plates in a back-and-forth and side-to-side manner; the use of a circular motion will cause the cells to unevenly pool in the center of the wells. Human hepatocytes handled in this manner will attach to the plates in 2-4 hours, however, if minimal handling is desired, the cells can be allowed to attach overnight.

Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention unless specified.

## EXAMPLE 1

## Refreezing of Thawed Hepatocyte Preparations

Cryopreserved hepatocytes are thawed and refrozen as indicated below.

Materials: 30 cc syringe, two couplers, PERCOLL® in a 1 L bag, INVITROGRO™ CP-2 medium in a 2 L bag, 1-2 L autoclaved beaker, heater, waterbath, centrifuge tube rack.

## Procedure:

- 1) Set up a recirculating waterbath heater at 37-42° C.
- 2) Add approximately 200-400 mls of INVITROGRO™ CP medium to a 1-2 L beaker. Equip Biological Safety Cabinet with a manual pipet or a liquid handling robot.

14

- 3) Remove approximately 50 cryovials from dewar receptacle and quickly place them in 2 test tube racks. When possible, space vials apart.

- 4) Submerge solid cell suspensions into heated waterbath until the ice chunks can be dislodged when the vial is inverted.

- 5) Pour cell suspension from each vial into the beaker. Add 1 ml of INVITROGRO™ CP medium from the small beaker into each vial to rinse and pour contents into the beaker. Transfer thawed cell suspension into a 1 L sterile bag.

- 6) Attach bag, INVITROGRO™ CP medium in a 2 L bag and PERCOLL® bagged at 30% onto COBE® automated cell processor (a centrifugal system incorporating a flexible membrane that allows the removal of fluids while spinning through use of a rotating seal, hydraulic pump and flexible membrane) and process according to standard practices.

- 7) Perform a cell count.

- 8) Cryopreserve cell suspension.

PERCOLL/REDIGRAD™ (Amersham Biosciences) is employed for the PERCOLL® density centrifugation. PERCOLL® is composed of colloidal silica coated with polyvinylpyrrolidone (PVP). The REDIGRAD™ formulation is also composed of colloidal silica but is covalently coated with silane. These coatings are thought to render the material non-toxic and ideal for use with biological materials. Both particles have a density of 1.13 g/ml. Centrifugation of sample in the presence of PERCOLL/REDIGRAD™ results in the spontaneous formation of a density gradient due to the heterogeneity of particle sizes in the medium.

PERCOLL/REDIGRAD™ is best used in balanced salt solutions, such as physiological saline (0.15 M NaCl), although 0.25 M sucrose may be employed. The addition of 9 parts (v/v) of PERCOLL/REDIGRAD™ to 1 part (v/v) of either 1.5 M NaCl, 10× concentrated cell culture medium, or 2.5 M sucrose will result in a solution adjusted to about 340 mOsm/kg H<sub>2</sub>O. Solutions of different osmotic pressure can be produced by adjusting the relative volumes of PERCOLL/REDIGRAD™ and salt or sucrose solution. (Vincent, R. et al. (1984) "Adjustment Of The Osmolality Of Percoll For The Isopycnic Separation Of Cells And Cell Organelles," Anal. Biochem. 141(2):322-328). The final adjustment to the required osmolality can be carried out by the addition of salts or distilled water. Concentrations other than 10× physiological saline may also be used satisfactorily.

PERCOLL/REDIGRAD™ will form self-generated gradients by centrifugation in fixed-angle rotor heads after 15 minutes. Hepatocytes can be separated by centrifugation at 50-100 g<sub>sw</sub> in fixed-angle or swinging bucket rotor heads after 10-30 minutes.

## EXAMPLE 2

## Variation of Primary Hepatocyte Samples

To illustrate the sample-to-sample variation of different sources of individual (unpooled) hepatocytes, hepatocytes are isolated from 82 different donors and analyzed for cell viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPI, TEST, TOLB, PHEN, and CZX. The results are shown in Table III.

US 7,604,929 B2

15

16

TABLE III

Variation of Hepatocyte Samples												
Lot No.	Sex	% V	COUM	DEX	ECOD	7- HCG	7- HCS	MEPH	TEST	TOLB	PHEN	CZX
067	M	62%	67	1	70	231	24	2	44	35	27	24
086	F	74%	51	23	10	50	9	1	38	13	BQL	18
089	F	77%	25	21	8	23	6	1	11	13	BQL	29
090	F	74%	30	25	7	13	BQL	2	19	15	BQL	16
091	F	73%	13	29	66	44	10	12	252	36	27	36
094	F	67%	41	12	37	24	4	21	126	40	19	87
099	F	86%	21	15	7	4	BQL	1	60	10	BQL	22
104	M	81%	63	21	44	247	23	2	58	37	8	20
105	M	67%	59	15	24	38	14	1	29	27	12	27
110	F	77%	45	24	35	23	4	6	206	11	54	36
111	F	71%	4	10	9	2	3	3	147	2	19	19
114	F	75%	39	23	21	10	5	5	99	TBD	3	45
122	M	79%	26	30	29	80	5	1	42	23	4	25
129	F	90%	4	24	27	67	18	1	16	33	10	51
ACU	F	81%	53	8	25	74	18	8	80	16	4	23
AIT	F	83%	45	29	13	118	14	BQL	82	15	11	7
AOK	M	73%	60	21	58	283	64	5	86	30	24	21
ATR	M	73%	7	11	1	39	11	BQL	11	8	3	4
AVF	M	70%	59	13	50	210	29	BQL	54	37	11	24
BTP	M	88%	66	29	36	214	25	3	50	45	11	12
CEC	M	86%	47	26	17	105	27	21	32	57	38	36
CEK	F	80%	55	2	39	141	5	16	302	41	7	16
CHD	F	77%	30	14	53	471	42	4	28	23	13	26
CPN	M	81%	28	6	40	100	13	2	168	14	17	21
ECM	M	85%	8	11	10	55	18	6	81	18	21	9
EFA	M	69%	9	9	35	47	5	18	66	12	47	67
EHF	F	90%	88	3	56	291	45	1	248	21	45	43
EJR	F	75%	89	14	32	288	43	8	62	43	1	41
ENR	M	73%	69	28	27	124	31	107	77	36	38	32
EOB	M	88%	14	11	18	65	9	31	49	14	21	35
ETR	F	88%	30	1	34	13	13	7	13	13	37	69
EVY	M	80%	2	20	23	218	77	33	24	25	17	38
FNL	M	85%	17	27	62	282	32	6	6	50	14	24
FRW	M	75%	46	22	16	106	17	48	25	54	44	8
GBE	F	77%	5	49	31	165	20	2	16	19	5	54
GNG	F	74%	57	17	33	54	8	5	95	22	16	22
GTV	F	71%	32	6	8	47	7	BQL	40	28	16	11
GUY	M	92%	65	12	11	73	12	20	90	13	5	8
HHG	M	83%	3	8	14	251	29	BQL	28	12	4	40
HOU	M	90%	43	28	39	175	15	4	69	40	57	44
ICJ	M	74%	134	20	60	287	17	BQL	129	82	28	7
IEM	M	88%	34	17	23	129	34	72	48	23	19	34
IHR	F	76%	17	43	8	84	9	9	93	46	41	7
LID	M	86%	36	31	50	307	54	1	142	49	21	51
IRX	F	73%	57	5	40	172	24	12	113	43	6	18
JUL	M	82%	7	11	3	41	9	7	23	12	2	3
KKS	M	83%	1	8	27	319	38	BQL	61	17	17	42
KPT	F	83%	9	12	32	248	30	55	65	26	56	32
KRJ	F	76%	6	40	76	359	37	1	11	61	23	20
KRM	F	78%	126	36	55	83	17	103	98	46	74	44
KSE	M	73%	65	27	52	206	74	21	123	42	93	16
KZO	F	82%	38	16	38	262	8	6	75	32	39	20
LAE	M	76%	58	15	50	294	22	14	67	63	125	21
MOF	F	91%	79	17	29	10	12	2	85	5	7	46
MRS	M	72%	119	21	110	450	50	2	675	54	68	28
MTR	F	69%	2	33	23	218	3	5	38	67	39	8
MYO	F	94%	40	24	9	24	BQL	BQL	12	7	BQL	11
NFX	F	79%	36	32	13	130	6	15	76	25	20	10
NQT	M	85%	76	12	39	80	23	2	151	14	20	34
OAU	F	81%	47	26	24	86	8	6	85	46	53	13
OZL	M	76%	16	15	61	300	109	3	165	29	17	43
PPM	F	87%	21	1	11	67	10	3	116	8	15	33
PXK	M	80%	86	35	63	433	78	2	109	62	32	60
QWO	F	77%	16	32	29	300	21	9	50	10	BQL	15
REL	F	77%	40	20	15	109	9	65	100	33	75	10
RFA	F	78%	130	42	49	444	52	6	195	30	28	17
RKB	F	95%	42	16	16	100	8	3	36	17	20	19
RML	F	76%	BQL	6	45	129	31	14	152	24	42	29
RNG	F	91%	119	14	97	298	27	177	207	34	71	41
ROE	F	82%	73	24	36	302	37	2	55	17	2	51
SEO	F	72%	36	25	18	106	9	66	102	50	81	11
SQJ	F	74%	115	12	100	285	19	175	210	30	81	42
SRA	M	79%	50	6	71	409	84	10	23	28	18	44
TPZ	F	83%	120	13	101	301	26	171	204	31	82	41

US 7,604,929 B2

17

18

TABLE III-continued

Variation of Hepatocyte Samples												
Lot No.	Sex	% V	COUM	DEX	ECOD	7-HCG	7-HCS	MEPH	TEST	TOLB	PHEN	CZX
TSR	F	82%	47	66	58	175	20	BQL	6	77	16	34
VCM	M	82%	47	28	79	415	110	0.2	94	16	4	215
VEN	F	70%	79	69	89	328	33	2	32	58	48	81
VTA	M	78%	32	1	25	84	12	5	120	21	40	15
WWM	M	84%	42	1	27	127	12	6	58	21	16	37
ZAG	M	85%	35	28	39	96	73	1	11	42	17	18
ZCR	M	80%	84	11	39	160	22	38	14	57	20	18
ZUJ	M	72%	6	33	31	320	29	13	25	34	3	13

BQL (Below Quantitation Limit)

TBD (To Be Determined)

## EXAMPLE 3

## Characterization of Pooled Hepatocytes

Cryopreserved pooled lots of hepatocytes are prepared and analyzed for post-thaw viability and enzyme function. The following metabolic activities are evaluated: COUM, DEX, ECOD, 7-HCG, 7-HCS, MEPH, TEST, TOLB, PHEN, and CZX.

Six lots of pooled hepatocytes, comprising either five-donor pools or ten-donor pools, are prepared as described above. Hepatocytes are harvested from individual donors and then cryopreserved as individual lots using liquid nitrogen as freezing agent. Cryopreservation is accomplished by suspending the hepatocytes into freezer-safe vials containing a medium having approximately 10% DMSO and approxi-

20 The cell suspension is centrifuged at 100 g for 20 minutes. The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL. A second solution containing 20% DMSO and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared. The 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes. The resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from individual lots are then pooled to form pooled hepatocyte preparations whose cells have functional assay values within desired ranges.

35 The pooled lots are then cryopreserved. Table IV below shows the results of the post-thaw viability ("% V") and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D.  $\pm 6\%$ ).

TABLE IV

Summary of Pooled Hepatocyte Lot Data											
Pool	% V	COUM	DEX	ECOD	7-HCG	7-HCS	MEPH	TEST	TOLB	PHEN	CZX
MJJ <sup>a</sup>	89	63	28	65	301	44	12	70	61	50	62
YDJ <sup>a</sup>	72	66	30	80	470	41	1	165	31	27	71
APD <sup>b</sup>	79	79	21	55	276	43	2	112	22	26	30
HMB <sup>b</sup>	76	61	18	70	231	46	3	151	23	20	83
IUJ <sup>b</sup>	75	32	19	35	232	44	2	124	32	11	42
RKS <sup>b</sup>	81	84	20	73	336	53	2	131	28	23	55

<sup>a</sup>5-donor lots<sup>b</sup>10-donor lots

mately 90% Cryopreservation Medium. The dispensed hepatocytes are then frozen in a controlled rate freezer until a final temperature of approximately  $-80^{\circ}\text{C}$ . is reached.

To form the pooled hepatocyte preparations, individual lots are thawed, and the viable cells are isolated by percoll gradient centrifugation. Vials of individual donor cryopreserved hepatocytes were thawed in a  $37^{\circ}\text{C}$ . waterbath (perhaps it would be better to give a range such as  $30-40^{\circ}\text{C}$ . waterbath?) for 60-90 seconds. The thawed cells are decanted into  $37^{\circ}\text{C}$ . media containing 30% Isotonic Percoll and 70% CP-2 media.

For comparison, Table V below shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are cryopreserved (i.e., subjected to one cycle of cryopreservation). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing cryopreserved cells that approximate the enzyme function of "average" hepatocytes for a wide variety of enzymes.

US 7,604,929 B2

19

20

TABLE V

Summary of Pooled Hepatocyte Lot Data											
	% V	COUM	DEX	ECOD	7-HCG	7-HCS	MEPH	TUST	TOLB	PHEN	CZX
Avg	79	37	17	51	276	27	8	35	35	15	19
High	95	134	69	110	471	110	177	675	82	125	215
Low	62	6	1	31	231	24	2	25	34	5	13

## EXAMPLE 3

## Characterization of the Viability of Pooled Hepatocytes After Thawing

A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO<sub>2</sub>. The viability of the hepatocytes is then measured at time-points for up to six hours. Table VI shows the results of this analysis, wherein, at six hours, 39% of the hepatocytes remained viable.

TABLE VI

Post-Thaw Viability Analysis of a Pooled Hepatocyte Lot	
Timepoint	% Viability *
T = 0	88%
0.5 hr	79%
1.0 hr	84%
2.0 hr	79%
3.0 hr	73%
4.0 hr	67%
6.0 hr	60%

\* viability determined by Trypan Blue

All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.

What is claimed is:

1. A method of producing a desired preparation of multi-cryopreserved hepatocytes, said hepatocytes, being capable of being frozen and thawed at least two times, and in which greater than 70% of the hepatocytes of said preparation are viable after the final thaw, said method comprising:

(A) subjecting hepatocytes that have been frozen and thawed to density gradient fractionation to separate viable hepatocytes from non-viable hepatocytes,

(B) recovering the separated viable hepatocytes, and

(C) cryopreserving the recovered viable hepatocytes to thereby form said desired preparation of hepatocytes without requiring a density gradient step after thawing the hepatocytes for the second time, wherein the hepatocytes are not plated between the first and second cryopreservations, and wherein greater than 70% of the hepatocytes of said preparation are viable after the final thaw.

2. The method of claim 1, wherein said density gradient fractionation comprises density centrifugation through polyvinylpyrrolidone-coated colloidal silica particles.

3. The method of claim 1, wherein said hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.

4. The method of claim 3, wherein said hepatocytes are human hepatocytes.

5. The method of claim 1, wherein said preparation comprises a pooled preparation of hepatocytes of multiple sources.

6. The method of claim 5, wherein said multiple sources are of the same gender, race, or health state.

7. The method of claim 5, wherein the hepatocytes of said pooled preparation of hepatocytes provide said pooled preparation with a desired level of a metabolic activity.

8. The method of claim 7, wherein said metabolic activity is selected from the group consisting of coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycoumarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenytoin 4-hydroxylase (MEPH), testosterone 6(β)-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), and chlorzoxazone 6-hydroxylase (CZX).

9. The method of claim 1, wherein greater than 80% of the hepatocytes of said preparation are viable.

10. A method of investigating in vitro drug metabolism comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic, and determining the metabolic fate of the xenobiotic, or the effect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof, wherein the hepatocytes have been frozen and thawed at least two times, and wherein greater than 70% of the hepatocytes of said preparation are viable without requiring a density gradient step after thawing the hepatocytes for the second time, wherein the hepatocytes are not plated between the first and second cryopreservations.

11. The method of claim 5, wherein said multiple sources are of different gender, race or health state.

\* \* \* \* \*

## **EXHIBIT D**

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
1. A method of producing a desired preparation of multi-cryopreserved hepatocytes,	a preparation of multi-cryopreserved hepatocytes is a composition of hepatocytes that have been frozen and thawed at least two times.	<p>Claims 1, 3, 5, and 7</p> <p>"In particular, the invention concerns methods of processing <b>preparations</b> of cells, especially hepatocytes, so as to permit their <b>repeated cryopreservation and thawing</b> while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been <b>repeatedly cryopreserved and thawed</b>." (col. 4, lines 12-17).</p> <p>"'cell <b>preparation</b>' denotes a liquid or frozen composition of cells from one or more sources" (col. 5, lines 32-33)</p> <p>"'hepatocyte <b>preparation</b>' denotes a composition of liver cells from one or more sources." (col. 5, lines 34-35),</p> <p>"'multi-cryopreserved hepatocyte <b>preparation</b>' denotes a hepatocyte <b>preparation</b> that has been frozen and thawed at least two times). Such preparations may have been frozen and thawed three, four, five, or more times." (col. 5, lines 47-51).</p> <p>"'pooled <b>preparation</b>' denotes a cell (e.g. hepatocyte) preparation in which the cells (e.g. hepatocytes) are derived from two, three, four, five, or more different sources" (col. 5, lines 52-54).</p>
said hepatocytes, being capable of being <b>frozen</b> and thawed at least two times,	<b>frozen</b> is changing from a liquid state to a solid state. In context of Claim 1, <b>frozen</b> means cryopreserved.	<p>Claim 1</p> <p>"The ability to recover viable thawed cells has been found to depend on multiple factors, such as the <b>rate of freezing</b>, the concentration of hepatocytes, the type of <b>cryoprotectant</b> employed, and the <b>final cooling temperature</b>." (col. 2, lines 56-60)</p> <p>"The art has developed various <b>freezing</b> procedures, all designed to minimize or prevent the occurrence of intracellular ice. The freezing rates typically vary from -0.05° C/min to -50°C./min." (col. 2, line 65 – col. 3, line 2).</p> <p>"In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their <b>repeated cryopreservation</b> and thawing while retaining substantial viability. (col. 4, lines 12-15).</p> <p>"subjecting hepatocytes that have been <b>frozen</b> and thawed to density gradient fractionation</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
		<p>(especially percoll density centrifugation) to separate viable hepatocytes from non-viable hepatocytes" (col. 4, lines 44-47).</p> <p>"Preferably <b>cryopreserved</b> using <b>liquid nitrogen</b>." (col. 7, lines 33-34).</p> <p>"The dispensed hepatocytes are then preferably <b>cryopreserved</b> using a controlled rate <b>freezing</b> process, most preferably at a <b>freezing</b> rate of between about -1° C./min to about -25° C./min until a final temperature of about -90° C. is reached. During the initial phase of the cryopreservation process, seeding may be employed to induce controlled crystallization or ice formation in cell suspensions that have already been cooled to below the freezing point of the culture medium." (col. 8, lines 33-41)</p> <p>"Once the desired final temperature has been reached, the <b>frozen</b> cell samples may be transferred to <b>liquid nitrogen freezers</b> for prolonged storage." (col. 8, lines 46-48).</p> <p>"In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent <b>refreezing</b>. Density gradient centrifugation is preferably employed for this purpose." (col. 10, lines 30-33).</p> <p>"<b>Cryopreserved</b> preparations that result from the <b>freezing</b> of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more. Such high viabilities enable the present invention to accomplish the <b>repeated freezing</b> and thawing of hepatocytes without unacceptable losses of cells or the need for ever greater samples sources." (col. 10, lines 61-67).</p> <p>"Hepatocytes are harvested from individual donors and then <b>cryopreserved</b> as individual lots using <b>liquid nitrogen as freezing agent</b>. Cryopreservation is accomplished by suspending the hepatocytes into freezer-safe vials containing a medium having approximately 10% DMSO and approximately 90% Cryopreservation Medium. The dispensed hepatocytes are then <b>frozen</b> in a <b>controlled rate freezer</b> until a final temperature of approximately -80° C. is reached." (col. 17, lines 34-60).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
and in which greater than 70% of the hepatocytes of said preparation are viable after the final thaw, said method comprising:	the hepatocytes of said preparation are viable after the final thaw are the percentage of living hepatocytes relative to the total hepatocyte population in the preparation, when determined after the final thaw.	<p>Claim 1</p> <p>"In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining <b>substantial viability</b>." (col. 4, lines 12-15).</p> <p>"The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining <b>substantial viability</b>." (col. 5, lines 11-15).</p> <p>"The <b>viability</b> of the isolated hepatocytes may be determined using any of a variety of methods. Preferable, such <b>viability</b> will be determined using the Trypan blue exclusion method ... Thus the phrases '<b>viable hepatocytes</b>' or '<b>percent viability</b>', as used herein, refers to <b>hepatocyte viability</b> as assessed using the method of Trypan Blue exclusion." (col. 7, lines 22-30)</p> <p>"If desired, the total cell count and the number of <b>viable cells</b> may be determined using the Trypan Blue exclusion method." (col. 9, lines 54-55).</p> <p>"Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a <b>post-thaw cell viability</b> of greater than 50% and more preferably 70% or more. (col. 10, lines 61-64).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
(A) subjecting hepatocytes that have been frozen and thawed to <b>density gradient fractionation</b> to separate viable hepatocytes from non-viable hepatocytes,	<b>density gradient fractionation</b> is a process for separating viable hepatocytes from non-viable hepatocytes based on their density.	<p>Claims 1 and 2</p> <p>"In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent refreezing. <b>Density gradient centrifugation</b> is preferably employed for this purpose." (col. 10, lines 30-33).</p> <p>"a 30% PERCOLL® <b>gradient centrifugation procedure</b> may be employed" (col. 10, lines 33-35).</p> <p>"PERCOLL/REDIGRAD® ... is employed for the PERCOLL® <b>density centrifugation</b>. PERCOLL® is composed of colloidal silica coated with polyvinylpyrrolidone (PVP). The REDIGRAD® formulation is also composed of colloidal silica but is covalently coated with silane. These coatings are thought to render the material non-toxic and ideal for use with biological materials. Both particles have a density of 1.13 g/ml. Centrifugation of sample in the presence of PERCOLL/REDIGRAD® results in the <b>spontaneous formation of a density gradient due to the heterogeneity of particle sizes</b> in the medium....PERCOLL/REDIGRAD® will form <b>self-generated gradients</b> by centrifugation in fixed-angle rotor heads after 15 minutes. Hepatocytes can be separated by centrifugation at 50-100 g<sub>w</sub> in fixed-angle or swinging bucket rotor heads after 10-30 minutes." (col. 14, lines 22-54)</p> <p>To form the pooled hepatocyte preparations, individual lots are thawed, and the viable cells are isolated by <b>percoll gradient centrifugation</b>. Vials of individual donor cryopreserved hepatocytes were thawed in a 37° C. waterbath ... for 60-90 seconds. The thawed cells are decanted into 37° C. media containing 30% <b>Isotonic Percoll</b> and 70% CP-2 media. (col. 17, lines 60-67).</p> <p>"The supply of such tissue is inconsistent and often geographically inconvenient in light of <b>the limited functional lifespan of liver tissue</b>" (col. 2, lines 30-32).</p> <p>"subjecting hepatocytes that have been frozen and thawed to density gradient fractionation (especially <b>percoll density centrifugation</b>) to separate viable hepatocytes from non-viable hepatocytes" (col. 4, lines 44-47).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
(B) recovering the separated viable hepatocytes, and	Recovering is the process of collecting separated viable hepatocytes.	<p>Claim 1</p> <p>“recovering the separated viable hepatocytes, and (C) cryopreserving the recovered viable hepatocytes to thereby form the desired preparation of hepatocytes.” (col. 4, lines 48-50).</p> <p>“Recovered cells may be reformulated for use in DNA, mRNA or proteomic studies or in studies of metabolic polymorphisms.” (col. 10, lines 19-21).</p> <p>“The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL. A second solution containing 20% DMSO and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared. The 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes. The resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from individual lots are then pooled to form pooled hepatocyte preparations whose cells have functional assay values within desired ranges” (col. 18, lines 22-35).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
(C) cryopreserving the recovered viable hepatocytes to thereby form said desired preparation of hepatocytes without requiring a density gradient step after thawing the hepatocytes for the second time,	<p>recovered viable hepatocytes are the collected living hepatocytes which have been subjected to a density gradient fractionation prior to re-cryopreservation.</p> <p>without requiring a density gradient step after thawing the hepatocytes for the second time means that the claimed process does not require a density gradient fractionation step after thawing the hepatocytes a second time.</p>	<p>Claim 1</p> <p>"The ability to recover viable thawed cells has been found to depend on multiple factors, such as the rate of freezing, the concentration of hepatocytes, the type of cryoprotectant employed, and the final cooling temperature." (col. 2, lines 56-60)</p> <p>"recovering the separated viable hepatocytes, and (C) cryopreserving the recovered viable hepatocytes to thereby form the desired preparation of hepatocytes." (col. 4, lines 48-49).</p> <p>"Recovered cells may be reformulated for use in DNA, mRNA or proteomic studies or in studies of metabolic polymorphisms." (col. 10, lines 19-21).</p> <p>-----</p> <p>Claim 1</p> <p>The '929 Prosecution History:</p> <p>Exhibit F at Tab 22 (Reply to Office Action dated 8-15-08)</p> <p>Exhibit F at Tab 21 (Office Action dated 11-13-08)</p> <p>Exhibit F at Tab 20 (Reply Office Action dated 2-12-09)</p> <p>Exhibit F at Tab 19 (Final Office Action dated 5-12-09)</p> <p>Exhibit F at Tab 17 (Reply to Office Action dated 5-22-09)</p> <p>Exhibit F at Tab 16 (Advisory Action dated 7-16-09)</p> <p>Exhibit F at Tab 13 (Notice of Allowability dated 8-20-09)</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
wherein the hepatocytes are not <b>plated</b> between the first and second cryopreservations, and	<b>plated</b> means to have placed hepatocytes on a plate containing attachment substrates (e.g., collagen or extra-cellular matrix proteins).	<p>Claims 1 and 10</p> <p>"If desired, the cryopreserved hepatocytes may be <b>plated</b> on to collagen-coated tissue culture plates, or tissue culture plates coated with other extracellular matrix proteins including but not limited to laminin, fibronectin, entactin, poly-L-lysine, gelatin, or any combination thereof. Preferably, this is accomplished by diluting an appropriate volume (e.g., 0.2 ml to 2.5 ml) of diluted cells (e.g., cells having a concentration of approximately <math>0.7 \times 10^6</math> cells/ml) onto the plates. For <b>plating</b> on a 96-well microtiter plate, it is desirable to further dilute the cell suspension to a concentration of <math>0.35 \times 10^6</math> cells/ml with InVivoGRO CP medium, and to add 100 <math>\mu</math>l of the cell suspension to each well. It is preferred to even distribute the cells in the wells. This can be accomplished by gently <b>shaking the plates</b> in a back-and-forth and side-to-side manner; the use of a circular motion will cause the cells to unevenly pool in the center of the wells. Human hepatocytes handled in this manner will attach to the <b>plates</b> in 2-4 hours, however, if minimal handling is desired, the cells can be allowed to <b>attach</b> overnight." (col. 13, lines 25-43)</p> <p>"A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a <b>12-well plate</b>, and incubated at 37° C. with 5% CO<sub>2</sub>." (col. 19, lines 17-24).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
wherein greater than 70% of the hepatocytes of said preparation are viable after the final thaw.	Final thaw is at least the second thaw.	Claims 1 and 10 <p>"The pooled lots are then cryopreserved. Table IV below shows the results of the post-thaw viability ("% V") and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D. +/- 6%)... For comparison, Table V below shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are cryopreserved (i.e., subjected to one cycle of cryopreservation). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing cryopreserved cells that approximate the enzyme function of 'average' hepatocytes for a wide variety of enzymes." (col. 18, lines 36-67)</p> <p>-----</p> <p>Claims 1 and 10          "In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining <b>substantial viability</b>." (col. 4, lines 12-15).          "The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining <b>substantial viability</b>." (col. 5, lines 11-15).          "The <b>viability</b> of the isolated hepatocytes may be determined using any of a variety of methods. Preferable, such <b>viability</b> will be determined using the Trypan blue exclusion method... Thus the phrases '<b>viable hepatocytes</b>' or '<b>percent viability</b>', as used herein, refers to <b>hepatocyte viability</b> as assessed using the method of Trypan Blue exclusion." (col. 7, lines 22-30)          "If desired, the total cell count and the number of <b>viable cells</b> may be determined using the Trypan Blue exclusion method." (col. 9, lines 54-55).          "Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a <b>post-thaw cell viability</b> of greater than 50% and more preferably 70% or more. (col. 10, lines 61-64).</p>
	the hepatocytes of said preparation are viable after the final thaw is the percentage of living hepatocytes relative to the total cell population in the preparation, when determined after the final thaw.	

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
10. A method of investigating <b>in vitro</b> drug metabolism comprising:	in vitro drug metabolism is the study of how compounds or substances are metabolized in a simulated biological system.	<p>Claim 10</p> <p>"The invention also concerns a method of investigating <b>in vitro</b> drug metabolism...determining the <b>metabolic fate</b> of the xenobiotic, or the <b>effect of the xenobiotic</b> on the hepatocytes or on an enzyme or metabolic activity thereof" (col. 4, line 65-col. 5, line 3)</p> <p>"In particular, <b>multi-cryopreserved hepatocyte preparations</b> may be used in <b>in vitro drug metabolism</b> studies (for example, in identifying <b>hepatocytes</b> with unique characteristics (e.g., metabolic polymorphisms, genetic polymorphisms, etc.) in studies on the <b>metabolic fate of the xenobiotic</b> and studies on the effect of the xenobiotic in <b>altering the drug-metabolizing enzyme profile of the hepatocytes</b>, in inhibition studies to determine the <b>IC<sub>50</sub> of xenobiotics</b> on liver enzymes and functions (e.g. cholesterol metabolism), in gene induction studies with <b>xenobiotics</b>, in protein induction studies with <b>xenobiotics</b>, in toxicity assessment of <b>xenobiotics</b> on hepatocytes, transport studies with <b>xenobiotics</b> (e.g. studies on P-glycoprotein transport systems, organic ion transporters, organic cation transporters, etc.), in <b>metabolic clearance studies with xenobiotics</b>, and in efficacy assays (e.g. lipoprotein processing, gluconeogenesis, protein secretion etc.)." (col. 9, line 67-col. 10, line 15)</p> <p>"Multi-cryopreserved hepatocyte preparations may also be used in <b>metabolic clearance</b> studies and efficacy assays (e.g., lipoprotein processing, gluconeogenesis, protein secretion, etc.)" (col. 10, lines 20-23)</p> <p>"Such composite hepatocyte preparations may thus be formulated so as to provide a preparation having the <b>metabolic activities</b> of an 'average' hepatocyte sample or a preparation whose hepatocyte enzyme functions approximate the hepatocyte enzyme functions of freshly isolated hepatocytes. Such <b>metabolic activities</b> may include, for example, some or all of the following <b>enzymatic activities</b>: coumarin 7-hydroxylase (COUM), dextromethorphan O-demethylase (DEX), 7-ethoxycoumarin O-deethylase (ECOD), activities responsible for the phase II metabolism of 7-hydroxycoumarin (7-HCG and 7-HCS), mephenytoin 4-hydroxylase (MEPH), testosterone 6(beta.)-hydroxylase (TEST), tolbutamide 4-hydroxylase (TOLB), phenacetin O-deethylase (PHEN), or chlorzoxazone 6-hydroxylase (CZX)." (col. 11, lines 11-25) Also, Table I(cols. 11-12)</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
incubating hepatocytes of a multi-cryopreserved hepatocyte preparation	incubating is simulating certain biological conditions.	Claim 10 <p>"comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic" (col. 4, line 66-col. 5, line 1)</p> <p>"A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO<sub>2</sub>." (col. 19, lines 17-24).</p>
in the presence of a xenobiotic, and	xenobiotic is a substance foreign to the body.	Claim 10 <p>"comprising incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic" (col. 4, lines 66-67).</p> <p>"A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO<sub>2</sub>. The viability of the hepatocytes is then measured at time-points for up to six hours. Table VI shows the results of this analysis, wherein, at six hours, 39% [69%] of the hepatocytes remained viable." Also see Table VI for post-thaw viability levels. (col. 19, lines 17-40).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
determining the <b>metabolic fate</b> of the xenobiotic, or the affect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof,	<b>metabolic fate</b> is the modification of the chemical structure or the localization of the xenobiotic by the hepatocytes.	<p>Claim 10</p> <p>"In particular, <b>multi-cryopreserved hepatocyte preparations</b> may be used in <b>in vitro drug metabolism</b> studies (for example, in identifying <b>hepatocytes</b> with unique characteristics (e.g., metabolic polymorphisms, genetic polymorphisms, etc.) in studies on the <b>metabolic fate of the xenobiotic</b> and studies on the affect of the xenobiotic in altering the <b>drug-metabolizing enzyme profile of the hepatocytes</b>, in inhibition studies to determine the <b>IC<sub>50</sub> of xenobiotics</b> on liver enzymes and functions (e.g. cholesterol metabolism), in gene induction studies with <b>xenobiotics</b>, in protein induction studies with <b>xenobiotics</b>, in toxicity assessment of <b>xenobiotics</b> on hepatocytes, transport studies with <b>xenobiotics</b> (e.g. studies on P-glycoprotein transport systems, organic ion transporters, organic cation transporters, etc.), in <b>metabolic clearance studies with xenobiotics</b>, and in efficacy assays (e.g. lipoprotein processing, gluconeogenesis, protein secretion etc.)." (col. 9, line 67-col. 10, line 15)</p> <p>The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL. A second solution containing 20% DMSO and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared. The 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes. The resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from individual lots are then pooled to form pooled hepatocyte preparations whose cells have <b>functional assay values</b> within desired ranges. (col. 18, lines 22-35).</p>
wherein the hepatocytes have been frozen and thawed <b>at least two times</b> , and	<b>at least two times</b> means that the preparation of hepatocytes is at least frozen, thawed, frozen again, and then thawed again. The preparations may be frozen and thawed three, four, five or more times.	<p>Claims 1 and 10</p> <p>"In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their <b>repeated cryopreservation</b> and thawing while retaining substantial viability. (col. 4, lines 12-15).</p> <p>"In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their <b>repeated cryopreservation and thawing</b> while retaining substantial viability. The invention also concerns preparations of cells (e.g., hepatocytes) that have been <b>repeatedly cryopreserved and thawed</b>." (col. 4, lines 12-17).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
	<p><b>frozen</b> is changing from a liquid state to a solid state. In context of claim, frozen means cryopreserved.</p>	<p>"The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their <b>repeated cryopreservation and thawing</b> while retaining substantial viability." (col. 5, lines 11-15).</p> <p>"<b>multi-cryopreserved hepatocyte preparation</b>" denotes a hepatocyte preparation that has been frozen and thawed at least two times). Such preparations may have been frozen and thawed three, four, five, or more times." (col. 5, lines 47-51).</p> <p>"One aspect of the present invention concerns the ability to reformulate the <b>thawed</b> cells so that they may be <b>refrozen</b> and <b>rethawed</b> on one or more subsequent occasions." (col. 9, lines 61-63).</p> <p>"In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent <b>refreezing</b>. Density gradient centrifugation is preferably employed for this purpose." (col. 10, lines 30-33).</p> <p>"Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more. Such high viabilities enable the present invention to accomplish the <b>repeated freezing and thawing of hepatocytes</b> without unacceptable losses of cells or the need for ever greater samples sources." (col. 10, lines 61-67).</p> <p>--- Claims 1 and 10</p> <p>"The ability to recover viable thawed cells has been found to depend on multiple factors, such as the <b>rate of freezing</b>, the concentration of hepatocytes, the type of <b>cryoprotectant</b> employed, and the <b>final cooling temperature</b>." (col. 2, lines 56-60)</p> <p>"The art has developed various <b>freezing</b> procedures, all designed to minimize or prevent the occurrence of intracellular ice. The freezing rates typically vary from -0.05° C./min to -50°C./min." col. 2, line 65 – col. 3, line 2).</p> <p>"subjecting hepatocytes that have been <b>frozen</b> and thawed to density gradient fractionation (especially percoll density centrifugation) to separate viable hepatocytes from non-viable hepatocytes." (col. 4, lines 44-47).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
		<p>"Preferably cryopreserved using liquid nitrogen." (col. 7, lines 33-34).</p> <p>"The dispensed hepatocytes are then preferably cryopreserved using a controlled rate freezing process, most preferably at a freezing rate of between about -1° C./min to about -25° C./min until a final temperature of about -90° C. is reached. During the initial phase of the cryopreservation process, seeding may be employed to induce controlled crystallization or ice formation in cell suspensions that have already been cooled to below the freezing point of the culture medium." (col. 8, lines 33-41)</p> <p>"Once the desired final temperature has been reached, the frozen cell samples may be transferred to liquid nitrogen freezers for prolonged storage." (col. 8, lines 46-48).</p> <p>"In a preferred embodiment of the invention, such reformulation comprises separating viable and non-viable cells prior to a subsequent refreezing. Density gradient centrifugation is preferably employed for this purpose." (col. 10, lines 30-33).</p> <p>"Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a post-thaw cell viability of greater than 50% and more preferably 70% or more. Such high viabilities enable the present invention to accomplish the repeated freezing and thawing of hepatocytes without unacceptable losses of cells or the need for ever greater samples sources." (col. 10, lines 61-67).</p> <p>"Hepatocytes are harvested from individual donors and then cryopreserved as individual lots using liquid nitrogen as freezing agent. Cryopreservation is accomplished by suspending the hepatocytes into freezer-safe vials containing a medium having approximately 10% DMSO and approximately 90% Cryopreservation Medium. The dispensed hepatocytes are then frozen in a controlled rate freezer until a final temperature of approximately -80° C. is reached." (col. 17, lines 34-60).</p> <p>"The viable cells are recovered in cryopreservation media and counted. The viable cells are diluted to 20 million cells per mL. A second solution containing 20% DMSO and 80% cryopreservation media (equal volume to the cell suspension listed above) is prepared. The 20% DMSO and 80% cryopreservation media is slowly added to the cells suspension mixture. The addition takes 5-10 minutes. The resulting mixture is 10% DMSO, 90% cryopreservation media with cells at 10 million cells per mL. This solution is aliquoted into cryovials at 1.0 mL per vial. The cells are then cryopreserved. Viable cells from</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
		<p>individual lots are then pooled to form pooled hepatocyte preparations whose cells have functional assay values within desired ranges. The pooled lots are then <b>cryopreserved</b>." (col. 18, lines 22-36).</p> <p>"The pooled lots are then <b>cryopreserved</b>. Table IV below shows the results of the post-thaw viability ("% V") and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D. <math>\pm</math> 6%)... For comparison, Table V below shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are <b>cryopreserved</b> (i.e., subjected to one cycle of <b>cryopreservation</b>). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing <b>cryopreserved</b> cells that approximate the enzyme function of 'average' hepatocytes for a wide variety of enzymes." (col. 18, lines 36-67)</p> <p>"A common use of for <b>cryopreserved hepatocytes</b> is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled <b>cryopreserved hepatocytes</b>, the cells were thawed, aliquoted into the wells of a 12-well plate, and incubated at 37° C. with 5% CO<sub>2</sub>. The viability of the hepatocytes is then measured at time-points for up to six hours. Table VI shows the results of this analysis, wherein, at six hours, 39% of the hepatocytes remained viable." Also see Table VI for post-thaw viability levels. (col. 19, lines 17-40).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
wherein greater than 70% of the hepatocytes of said preparation are viable without requiring a density gradient step after thawing the hepatocytes for the second time,	<p>Final thaw is at least the second thaw.</p> <p>the hepatocytes of said preparation are viable after the final thaw is the percentage of living hepatocytes relative to the total cell population in the preparation, when determined after the final thaw</p>	<p>Claims 1 and 10</p> <p>"The pooled lots are then cryopreserved. Table IV below shows the results of the post-thaw viability ("% V") and enzyme function analysis of the pooled lots. As indicated in Table III, pools had an average viability of 79% (S.D. <math>\pm</math> 6%)... For comparison, Table V below shows summary data for a post-thaw viability and enzyme function analysis of eighty-one individual lots that are cryopreserved (i.e., subjected to one cycle of cryopreservation). This data confirms that the lot-to-lot variability of enzyme function found in individual hepatocyte sources is very high. The data confirms the desirability of employing pooled hepatocyte preparations for providing cryopreserved cells that approximate the enzyme function of 'average' hepatocytes for a wide variety of enzymes." (col. 18, lines 36-67)</p> <p>-----</p> <p>Claims 1 and 10</p> <p>"In particular, the invention concerns methods of processing preparations of cells, especially hepatocytes, so as to permit their repeated cryopreservation and thawing while retaining <b>substantial viability</b>." (col. 4, lines 12-15).</p> <p>"The present invention relates to novel cell compositions and methods for their preparation and use. In particular, the invention concerns methods of processing preparations of cells so as to permit their repeated cryopreservation and thawing while retaining <b>substantial viability</b>." (col. 5, lines 11-15).</p> <p>"The <b>viability</b> of the isolated hepatocytes may be determined using any of a variety of methods. Preferable, such <b>viability</b> will be determined using the Trypan blue exclusion method... Thus the phrases '<b>viable hepatocytes</b>' or '<b>percent viability</b>', as used herein, refers to <b>hepatocyte viability</b> as assessed using the method of Trypan Blue exclusion." (col. 7, lines 22-30)</p> <p>"If desired, the total cell count and the number of <b>viable cells</b> may be determined using the Trypan Blue exclusion method." (col. 9, lines 54-55).</p> <p>"Cryopreserved preparations that result from the freezing of a previously frozen-thawed preparation will preferably have a <b>post-thaw cell viability</b> of greater than 50% and more preferably 70% or more. (col. 10, lines 61-64).</p>

## STROM EXHIBIT D: CLAIM TERM CHART

<u>Claim</u>	<u>Proposed Interpretation</u>	<u>Support</u>
wherein the hepatocytes are <b>not plated</b> between the first and second cryopreservations.	<b>plated</b> means to have placed hepatocytes on a plate containing attachment substrates (e.g., collagen or extra-cellular matrix proteins).	<p>"If desired, the cryopreserved hepatocytes may be <b>plated</b> on to <b>collagen-coated tissue culture plates</b>, or <b>tissue culture plates</b> coated with other <b>extracellular matrix proteins</b> including but not limited to laminin, fibronectin, entactin, poly-L-lysine, gelatin, or any combination thereof. Preferably, this is accomplished by diluting an appropriate volume (e.g., 0.2 ml to 2.5 ml) of diluted cells (e.g., cells having a concentration of approximately <math>0.7 \times 10^6</math> cells/ml) onto the plates. For <b>plating</b> on a 96-well microtiter plate, it is desirable to further dilute the cell suspension to a concentration of <math>0.35 \times 10^6</math> cells/ml with InVitroGRO CP medium, and to add 100 <math>\mu</math>l of the cell suspension to each well. It is preferred to even distribute the cells in the wells. This can be accomplished by gently <b>shaking the plates</b> in a back-and-forth and side-to-side manner; the use of a circular motion will cause the cells to unevenly pool in the center of the wells. Human hepatocytes handled in this manner will attach to the <b>plates</b> in 2-4 hours, however, if minimal handling is desired, the cells can be allowed to <b>attach</b> overnight." (col. 13, lines 25-43)</p> <p>"A common use of for cryopreserved hepatocytes is to thaw the hepatocytes and then incubate them with various xenobiotics. For this purpose, it is preferred that the hepatocytes maintain their viability for at least several hours. To examine the post-thaw viability over time for one lot of pooled cryopreserved hepatocytes, the cells were thawed, aliquoted into the <b>wells of a 12-well plate</b>, and incubated at 37° C. with 5% CO<sub>2</sub>." (col. 19, lines 17-24).</p>

## **EXHIBIT E**

## STROM EXHIBIT E: COMPARISON CHART

<u>Claims of the '929 Patent</u>	<u>The CellZDirect Process</u>
<p>1. A method of producing a desired preparation of multi-cryopreserved hepatocytes,</p>	<p><b>"preparation of multi-cryopreserved hepatocytes"</b></p> <p><b>Exhibit E.1:</b> Document discloses that the viability of the cryopreserved hepatocytes ranges from 81%-90% and that the first thaw viability of Lot # HuP58 is 81%.</p> <p><b>Exhibit E.2:</b> Document discloses that CellZDirect's pooled hepatocyte catalog (SKU) numbers include HMCS3S and HMCS3L. For example, HMCS3S includes lot numbers: Hu0539-3, HuP2001-03, HuP53, HuP88, HuP89, and HuP94; and HMCS3L includes lot number HuP61. See <b>Exhibit E.11</b>.</p> <p><b>Exhibit E.3:</b> Document discloses that HuP58 has second post-thaw viability of 75%.</p> <p><b>Exhibit E.16:</b> Document discloses that "CellZDirect scientists, partnered with APS, Inc., have worked painstakingly to develop a large inventory of high quality human cryopreserved cells."</p> <p><b>Exhibit E.6:</b> Document discloses that Dr. Albert Li's chapter, entitled "Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes," from <i>Enzyme Inhibition In Drug Discovery and Development</i> at p. 428 that Figure presents details of a 10 donor twice-cryopreserved hepatocyte preparation, which preparation is HuP58 (sold by CellZDirect). Preparation of HuP58 includes preparing donor cryopreserved cells, thawing them, preparing the pool and re-cryopreserving. Figure 13.1 also discloses that the "cells have been cryopreserved and thawed twice" and that Figure 13.1 is courtesy of Invitrogen CellZDirect.</p> <p><b>Exhibit E.9:</b> Document discloses preparation of pre-pooled human hepatocytes. "To prepare the pre-pooled human hepatocytes, cryopreserved hepatocytes from individual donors are thawed, pooled and re-cryopreserved. We have developed an optimized procedure for the thawing and re-cryopreservation with no apparent loss of drug metabolizing enzyme activities in the pooled cells after the second thawing."</p> <p>In my opinion, "a person of ordinary skill in the art" would know that CellZDirect produces a preparation of multi-cryopreserved hepatocytes based upon this information.</p>

## STROM EXHIBIT E: COMPARISON CHART

Claims of the '929 Patent	The CellzDirect Process
<p>said hepatocytes, being capable of being <b>frozen and thawed</b> at least two times,</p>	<p><b>“frozen”</b>  <b>Exhibit E.3:</b> Document discloses that cryopreserved hepatocytes have a second thaw viability of 75%.</p> <p><b>Exhibit E.6:</b> Document discloses that Dr. Albert Li’s chapter, entitled “Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes,” from <i>Enzyme Inhibition In Drug Discovery and Development</i> at p. 428 that Figure presents details of a 10 donor twice-cryopreserved hepatocyte preparation, which preparation is HuP58 (sold by CellzDirect). Preparation of HuP58 includes preparing donor cryopreserved cells, thawing them, preparing the pool and re-cryopreserving. Figure 13.1 also discloses that the “cells have been cryopreserved and thawed twice” and that Figure 13.1 is courtesy of Invitrogen CellDirect.</p> <p><b>Exhibit E.9:</b> Document discloses preparation of pre-pooled human hepatocytes. “To prepare the pre-pooled human hepatocytes, cryopreserved hepatocytes from individual donors are thawed, pooled and re-cryopreserved. We have developed an optimized procedure for the thawing and re-cryopreservation with no apparent loss of drug metabolizing enzyme activities in the pooled cells after the second thawing.”</p> <p><b>“thawed”</b>  <b>Exhibits E.1 and E.7:</b> Provides detailed instruction for thawing and using cryopreserved hepatocytes.</p> <p><b>Exhibit E.6:</b> Same as above.</p> <p><b>Exhibit E.9:</b> Same as above.</p> <p>In my opinion, “a person of ordinary skill in the art” would know that the CellzDirect process satisfies these claim terms based upon this information.</p>
<p>and in which <b>greater than 70% of the hepatocytes of said preparation are viable</b> after the final thaw, said method comprising:</p>	<p><b>“greater than 70% of the hepatocytes of said preparation are viable”</b>  <b>Exhibit E.1:</b> Document discloses that the viability of the cryopreserved hepatocytes ranges from 81%-90% and that the first thaw viability of HuP58 is 81%.</p> <p><b>Exhibit E.3:</b> Document discloses that HuP58 has a post thaw viability of 75% in WEM thawing medium and 81% in CHRM medium.</p> <p>In my opinion, “a person of ordinary skill in the art” would know that the CellzDirect process satisfies these claim terms based upon this information.</p>

## STROM EXHIBIT E: COMPARISON CHART

Claims of the '929 Patent	The CellzDirect Process
<p>(A) subjecting hepatocytes that have been frozen and thawed to <b>density gradient fractionation</b> to separate viable hepatocytes from non-viable hepatocytes,</p>	<p><b>"density gradient fractionation"</b></p> <p><b>Exhibit E.3:</b> Document discloses that CellzDirect has 460 vials (originally 469) in inventory with viabilities greater than 70%. In my experience 469 vials of HuP58 would be extremely difficult to obtain with a viability of greater than 70%, and the supply of such liver tissue is inconsistent and often geographically inconvenient in light of the limited functional lifespan of liver tissue. Thus, it is my opinion that "a person of ordinary skill in the art" would know that to create this large inventory a density gradient fractionation step must be used between the first and second cryopreservation steps to separate the viable hepatocytes from non-viable hepatocytes.</p> <p><b>Exhibit E.10:</b> Document discloses that CellzDirect sells single donor cryopreserved human hepatocytes with average viabilities ranging from 71% to 88%. I calculated the average viability of these 41 donor lots to be 78.9%.</p> <p><b>Exhibit E.11:</b> Document discloses that CellzDirect sells pooled cryopreserved hepatocytes with average viabilities ranging from 75% to 85%. I calculated the average viability of these 7 pooled lots to be 79.4%.</p> <p>Given what is taught in the literature (<i>see Exhibit E.12 (Ostrowska)</i>), in my opinion, "a person of ordinary skill in the art" would know that one cryopreservation-thaw cycle will decrease the viability by an average of 16.9%. When I consider the average percent drop in viability due to one cryopreservation-thaw cycle, I would predict that the CellzDirect pooled cryopreserved hepatocytes (<b>Exhibit E.11</b>) should have a viability no greater than 62%. However, the actual viability of these pooled lots is 79.4%. <i>See Exhibit E.11</i>. Therefore, based upon this information, in my opinion, "a person of ordinary skill in the art" would know that CellzDirect used a density gradient fractionate step to separate the viable hepatocytes from non-viable hepatocytes between the first and second cryopreservation steps in order to achieve the average viability of 79.4%. Thus, the CellzDirect process satisfies these claim terms.</p>
<p>(B) <b>recovering</b> the separated viable hepatocytes, and</p>	<p><b>"recovering"</b></p> <p>In my opinion, "a person of ordinary skill in the art" would know that in order to practice the subsequent (C) step, CellzDirect must recover the separated viable hepatocytes from the first cryopreservation-thaw cycle. Thus, the CellzDirect process satisfies these claim terms.</p>

# STROM EXHIBIT E: COMPARISON CHART

Claims of the '929 Patent	The CellZDirect Process
<p>(C) cryopreserving the recovered viable hepatocytes to thereby form said desired preparation of hepatocytes without requiring a density gradient step after thawing the hepatocytes for the second time,</p>	<p><b>"recovered viable hepatocytes"</b></p> <p><b>Exhibit E.6:</b> Document discloses that Dr. Albert Li's chapter, entitled "Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes," from <i>Enzyme Inhibition In Drug Discovery and Development</i> at p. 428 that Figure presents details of a 10 donor twice-cryopreserved hepatocyte preparation, which preparation is HuP58 (sold by CellZDirect). Preparation of HuP58 includes preparing donor cryopreserved cells, thawing them, preparing the pool and re-cryopreserving. Figure 13.1 also discloses that the "cells have been cryopreserved and thawed twice" and that Figure 13.1 is courtesy of Invitrogen CellZDirect.</p> <p><b>Exhibit E.9:</b> Document discloses preparation of pre-pooled human hepatocytes. "To prepare the pre-pooled human hepatocytes, cryopreserved hepatocytes from individual donors are thawed, pooled and re-cryopreserved. We have developed an optimized procedure for the thawing and re-cryopreservation with no apparent loss of drug metabolizing enzyme activities in the pooled cells after the second thawing."</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellZDirect process satisfies these claim terms based upon this information.</p>
<p>wherein the hepatocytes are not plated between the first and second cryopreservations, and</p>	<p><b>"plated"</b></p> <p><b>Exhibit E.6:</b> Document discloses that Dr. Albert Li's chapter, entitled "Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes," from <i>Enzyme Inhibition In Drug Discovery and Development</i> at p. 428 that Figure presents details of a 10 donor twice-cryopreserved hepatocyte preparation, which preparation is HuP58 (sold by CellZDirect). Preparation of HuP58 includes preparing donor cryopreserved cells, thawing them, preparing the pool and re-cryopreserving. Figure 13.1 also discloses that the "cells have been cryopreserved and thawed twice" and that Figure 13.1 is courtesy of Invitrogen CellZDirect.</p> <p><b>Exhibit E.9:</b> Document discloses preparation of pre-pooled human hepatocytes. "To prepare the pre-pooled human hepatocytes, cryopreserved hepatocytes from individual donors are thawed, pooled and re-cryopreserved. We have developed an optimized procedure for the thawing and re-cryopreservation with no apparent loss of drug metabolizing enzyme activities in the pooled cells after the second thawing."</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellZDirect process satisfies these claim terms, because the CellZDirect process does not plate the hepatocytes between the first and second cryopreservation steps.</p>

## STROM EXHIBIT E: COMPARISON CHART

<u>Claims of the '929 Patent</u>	<u>The CellzDirect Process</u>
wherein greater than 70% of the hepatocytes of said preparation are viable after the final thaw.	<p><b>"70% of the hepatocytes . . . are viable after the final thaw"</b></p> <p><b>Exhibit E.3:</b> Document discloses that HuP58 has a post thaw viability of 75% in WEM thawing medium and 81% in CHRM medium.</p> <p><b>Exhibit E.1:</b> Document discloses that the viability of the cryopreserved hepatocytes ranges from 81%-90% and that the post thaw viability of HuP58 is 81%.</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon this information.</p>
3. The method of claim 1, wherein said hepatocytes are selected from the group consisting of human hepatocytes, porcine hepatocytes, simian hepatocytes, canine hepatocytes, feline hepatocytes, bovine hepatocytes, equine hepatocytes, ovine hepatocytes and rodent hepatocytes.	<p><b>Exhibit E.3:</b> Document discloses that HuP58 is a pooled preparation of hepatocytes from multiple sources (e.g., Caucasian male age 39, Caucasian male age 41, <i>etc.</i>).</p> <p><b>Exhibit E.15:</b> Document discloses that CellzDirect sells pooled preparations of hepatocytes from multiple cynomolgus monkey sources (e.g., Lot no. CYP10).</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon this information.</p>
4. The method of claim 3, wherein said hepatocytes are human hepatocytes.	<p><b>Exhibit E.3:</b> Document discloses that HuP58 is a pooled preparation of hepatocytes from multiple human sources (e.g., Caucasian male age 39, Caucasian male age 41, <i>etc.</i>).</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon this information.</p>
5. The method of claim 1, wherein said preparation comprises a pooled preparation of hepatocytes of multiple sources.	<p><b>Exhibit E.3:</b> Document discloses that HuP58 is a pooled preparation of hepatocytes from multiple sources (e.g., Caucasian male age 39, Caucasian male age 41, <i>etc.</i>).</p> <p><b>Exhibit E.15:</b> Document discloses that CellzDirect sells pooled preparations of hepatocytes from multiple cynomolgus monkey sources (e.g., Lot no. CYP10).</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon this information.</p>

**STROM EXHIBIT E: COMPARISON CHART**

<u>Claims of the '929 Patent</u>	<u>The CellzDirect Process</u>
<p>7. The method of claim 5, wherein the hepatocytes of said pooled preparation of hepatocytes provide said pooled preparation with a desired level of a metabolic activity.</p>	<p><b>Exhibit E.3:</b> Document discloses that HuP58 is a pooled preparation of hepatocytes from multiple sources (<i>e.g.</i>, Caucasian male age 39, Caucasian male age 41, <i>etc.</i>) that exhibits desired levels of metabolic activity (<i>e.g.</i>, CYP 3A4, CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, and CYP 2D6).</p> <p><b>Exhibit E.15:</b> Document discloses that CellzDirect sells pooled preparations of hepatocytes from multiple cynomolgus monkey sources (<i>e.g.</i>, Lot no. CYP 10) that exhibits desired levels of metabolic activity (<i>e.g.</i>, ECOD, 7-HCG, and 7-HCS).</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon this information.</p>

## STROM EXHIBIT E: COMPARISON CHART

<u>Claims of the '929 Patent</u>	<u>The CellZDirect Process</u>
<p>10. A method of investigating <b>in vitro drug metabolism</b> comprising:</p>	<p><b>"in vitro drug metabolism"</b>  <b>Exhibits E.8 and E.13:</b> Documents disclose that CellZDirect offers a variety of cryopreserved hepatocyte products useful for <i>in vitro</i> drug development applications and provide <i>in vitro</i> metabolism and drug-drug interaction services using cryopreserved hepatocytes.</p> <p><b>Exhibit E.7:</b> Document discloses that the CellZDirect cryopreserved hepatocyte products may be used for inhibition assays, which is a drug-drug interaction study.</p> <p>In my opinion, "a person of ordinary skill in the art" would know that CellZDirect or a customer would use CellZDirect's cryopreserved hepatocyte products for investigating <i>in vitro</i> drug metabolism., and thus the CellZDirect process satisfies these claim terms.</p>
<p><b>incubating</b> hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a <b>xenobiotic</b>, and</p>	<p><b>"incubating"</b>  <b>Exhibit E.3:</b> Document discloses that in order to obtain results, the xenobiotic (drug) must be in contact with (incubated) cells: "The cell suspension was aliquoted at <math>0.5 \times 10^6</math> cells/well into a 24-well non-coated plate containing the appropriate substrate and placed in a humidified incubator."</p> <p><b>"xenobiotic"</b>  <b>Exhibit E.7 and E.13:</b> In my opinion, "a person of ordinary skill in the art" would know that during the performance of these <i>in vitro</i> services, such as a drug metabolism study (see <b>Exhibits E.7 and E.13</b>), CellZDirect must expose the cryopreserved hepatocyte product to the xenobiotic (<i>i.e.</i>, the drug). Also "a person of ordinary skill in the art" would know that a customer would use CellZDirect's cryopreserved hepatocyte products by incubating hepatocytes of a multi-cryopreserved hepatocyte preparation in the presence of a xenobiotic.</p> <p>In my opinion, "a person of ordinary skill in the art" would know that the CellZDirect process satisfies these claim terms based upon this information.</p>
<p>determining the <b>metabolic fate</b> of the xenobiotic, or the affect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity thereof,</p>	<p><b>Exhibits E.8:</b> Documents disclose that the CellZDirect cryopreserved hepatocytes may be used to determine determining the metabolic fate of the xenobiotic, or the affect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity in applications such as "Inhibition," "Metabolic Stability," "Intrinsic Clearance," "Metabolic Profiling/Met ID," and "Induction" assays.</p> <p>In my opinion, "a person of ordinary skill in the art" would know that CellZDirect or the customers would use the CellZDirect cryopreserved hepatocyte products to determine the xenobiotic, or the affect of the xenobiotic on the hepatocytes or on an enzyme or metabolic activity, and thus the CellZDirect process satisfies these claim terms.</p>

**STROM EXHIBIT E: COMPARISON CHART**

<u>Claims of the '929 Patent</u>	<u>The CellzDirect Process</u>
wherein the hepatocytes have been <b>frozen and thawed</b> at least two times, and	In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon the information as explained above for Claim 1.
wherein greater than <b>70% of the hepatocytes</b> of said preparation are viable without requiring a <b>density gradient step</b> after thawing the hepatocytes for the second time,	In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon the information as explained above for Claim 1.
wherein the hepatocytes are <b>not plated</b> between the first and second cryopreservations.	In my opinion, "a person of ordinary skill in the art" would know that the CellzDirect process satisfies these claim terms based upon the information as explained above for Claim 1.